1
|
Zhang Z, Zhang L, Li J, Feng R, Li C, Liu Y, Sun G, Xiao F, Zhang C. Comprehensive analysis of m 6A methylome alterations after azacytidine plus venetoclax treatment for acute myeloid leukemia by nanopore sequencing. Comput Struct Biotechnol J 2024; 23:1144-1153. [PMID: 38510975 PMCID: PMC10950754 DOI: 10.1016/j.csbj.2024.02.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 02/29/2024] [Accepted: 02/29/2024] [Indexed: 03/22/2024] Open
Abstract
N6 adenosine methylation (m6A), one of the most prevalent internal modifications on mammalian RNAs, regulates RNA transcription, stabilization, and splicing. Growing evidence has focused on the functional role of m6A regulators on acute myeloid leukemia (AML). However, the global m6A levels after azacytidine (AZA) plus venetoclax (VEN) treatment in AML patients remain unclear. In our present study, bone marrow (BM) sample pairs (including pre-treatment [AML] and post-treatment [complete remission (CR)] samples) were harvested from three AML patients who had achieved CR after AZA plus VEN treatment for Nanopore direct RNA sequencing. Notably, the amount of m6A sites and the m6A levels in CR BMs was significantly lower than those in the AML BMs. Such a significant reduction in the m6A levels was also detected in AZA-treated HL-60 cells. Thirteen genes with decreased m6A and expression levels were identified, among which three genes (HPRT1, SNRPC, and ANP32B) were closely related to the prognosis of AML. Finally, we speculated the mechanism via which m6A modifications affected the mRNA stability of these three genes. In conclusion, we illustrated for the first time the global landscape of m6A levels in AZA plus VEN treated AML (CR) patients and revealed that AZA had a significant demethylation effect at the RNA level in AML patients. In addition, we identified new biomarkers for AZA plus VEN-treated AML via Nanopore sequencing technology in RNA epigenetics.
Collapse
Affiliation(s)
- Zaifeng Zhang
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology of National Health Commission, Beijing, China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, 9 DongDan Santiao, Beijing 100730, China
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Lili Zhang
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Jiangtao Li
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Chang Li
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology of National Health Commission, Beijing, China
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Ye Liu
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology of National Health Commission, Beijing, China
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Gaoyuan Sun
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Fei Xiao
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology of National Health Commission, Beijing, China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, 9 DongDan Santiao, Beijing 100730, China
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Chunli Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
2
|
Jia TZ, Feng R, Cui C, Chen Q, Cseri L, Zhou RF, Szekely G, Cao XL, Sun SP. Conductive nanofiltration membranes via in situ PEDOT-polymerization for electro-assisted membrane fouling mitigation. Water Res 2024; 252:121251. [PMID: 38324983 DOI: 10.1016/j.watres.2024.121251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/23/2023] [Revised: 01/15/2024] [Accepted: 01/31/2024] [Indexed: 02/09/2024]
Abstract
Nanofiltration (NF) membranes play a pivotal role in water treatment; however, the persistent challenge of membrane fouling hampers their stable application. This study introduces a novel approach to address this issue through the creation of a poly(3,4-ethylenedioxythiophene) (PEDOT)-based conductive membrane, achieved by synergistically coupling interfacial polymerization (IP) with in situ self-polymerization of EDOT. During the IP reaction, the concurrent generation of HCl triggers the protonation of EDOT, activating its self-polymerization into PEDOT. This interwoven structure integrates with the polyamide network to establish a stable selective layer, yielding a remarkable 90 % increase in permeability to 20.4 L m-2 h-1 bar-1. Leveraging the conductivity conferred by PEDOT doping, an electro-assisted cleaning strategy is devised, rapidly restoring the flux to 98.3 % within 5 min, outperforming the 30-minute pure water cleaning approach. Through simulations in an 8040 spiral-wound module and the utilization of the permeated salt solution for cleaning, the electro-assisted cleaning strategy emerges as an eco-friendly solution, significantly reducing water consumption and incurring only a marginal electricity cost of 0.055 $ per day. This work presents an innovative avenue for constructing conductive membranes and introduces an efficient and cost-effective electro-assisted cleaning strategy to effectively combat membrane fouling.
Collapse
Affiliation(s)
- Tian-Zhi Jia
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China
| | - Ru Feng
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China
| | - Chun Cui
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China
| | - Qian Chen
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China
| | - Levente Cseri
- Department of Chemical Engineering & Analytical Science, School of Engineering, The University of Manchester, The Mill, Sackville Street, Manchester, M1 3BB, United Kingdom
| | - Rong-Fei Zhou
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China; Suzhou Laboratory, Suzhou 215100, China
| | - Gyorgy Szekely
- Department of Chemical Engineering & Analytical Science, School of Engineering, The University of Manchester, The Mill, Sackville Street, Manchester, M1 3BB, United Kingdom; Chemical Engineering Program, Physical Science and Engineering Division (PSE), King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia; Advanced Membranes and Porous Materials Center, Physical Science and Engineering Division (PSE), King Abdullah University of Science and Technology (KAUST), Thuwal, 23955-6900, Saudi Arabia
| | - Xue-Li Cao
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China.
| | - Shi-Peng Sun
- State Key Laboratory of Materials-Oriented Chemical Engineering, Jiangsu Collaborative Innovation Center of Membrane Materials and Membrane Processes, Jiangsu Future Membrane Technology Innovation Center, College of Chemical Engineering, Nanjing Tech University, Nanjing, 211816, China; Suzhou Laboratory, Suzhou 215100, China.
| |
Collapse
|
3
|
Yao Y, Ye H, Fang W, Feng R, Zhang C, Zheng L, Lv H, Li J, Jing J. Dislocation Does Not Seem To Be an Absolute Factor Effecting the Short- to Medium-Term Poor Prognosis of Patients with Acetabular Posterior Wall Fracture. Z Orthop Unfall 2024. [PMID: 38423035 DOI: 10.1055/a-2265-0446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/02/2024]
Abstract
Dislocation is a complication of acetabular fractures involving the posterior wall, but whether dislocation is an absolute factor impacting the short- to medium-term prognosis of the hip joint remains controversial. This study aimed to compare the short- to medium-term clinical and radiological results among patients diagnosed with an acetabular fracture involving the posterior wall, with or without dislocation.Seventy-nine patients diagnosed with an acetabular fracture involving the posterior wall were retrospectively divided into posterior dislocation and non-dislocation groups. All fractures were open reduction + internal fixation with a plate screw combination through the single Kocher-Langenbeck approach. The short- to medium-term radiographic outcomes of follow-up were evaluated using the Matta radiologic grading system, while the clinical outcomes were evaluated using the modified Merle d'Aubigné-Postel evaluation system.The mean follow-up duration for all patients was 43.90 (range 24-75) months. Both groups achieved similar short- to medium-term clinical and radiographic results. There seems to be no significant differences between the two groups regarding the short- to medium-term assessment of clinical and radiographic results and the occurrence of postoperative complications (p > 0.05).In patients with acetabular fractures involving the posterior wall, hip dislocation is probably not an absolute determinant of a poor outcome. Even with early reduction, the short- to medium-term prognosis results appear similar to those of patients without dislocation.
Collapse
Affiliation(s)
- Yunfeng Yao
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Houlong Ye
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Wang Fang
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Ru Feng
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Chun Zhang
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Liujie Zheng
- Department of Orthopaedic Surgery, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Hao Lv
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Jun Li
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Juehua Jing
- Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
- Institute of Orthopaedics, Research Center for Translational Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China
| |
Collapse
|
4
|
Wang Y, Hu D, Liu Y, Yang L, Huang J, Zhou J, Guo L, Fan X, Huang X, Peng M, Cheng C, Zhang W, Feng R, Tian X, Yu S, Xu KF. Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report. QJM 2024; 117:75-76. [PMID: 37843443 PMCID: PMC10849871 DOI: 10.1093/qjmed/hcad235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Indexed: 10/17/2023] Open
Affiliation(s)
- Y Wang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - D Hu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Y Liu
- McKusick-Zhang Center for Genetic Medicine, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, China
| | - L Yang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Huang
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - J Zhou
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - L Guo
- Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Center, Beijing, China
| | - X Fan
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - X Huang
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - M Peng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - C Cheng
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - W Zhang
- Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - R Feng
- Department of Pathology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - X Tian
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - S Yu
- Clinical Genome Center, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangdong, China
| | - K -F Xu
- Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
5
|
Xiong D, Wei X, Huang W, Zheng J, Feng R. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma. Aging (Albany NY) 2024; 16:1049-1076. [PMID: 38240686 PMCID: PMC10866451 DOI: 10.18632/aging.205282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 10/15/2023] [Indexed: 02/06/2024]
Abstract
BACKGROUND/AIMS Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has significant prognostic heterogeneity. This study aimed to generate a prognostic prediction model based on autophagy-related genes for DLBCL patients. METHODS Utilizing bioinformatics techniques, we analyzed the clinical information and transcriptome data of DLBCL patients from the Gene Expression Omnibus (GEO) database. Through unsupervised clustering, we identified new autophagy-related molecular subtypes and pinpointed differentially expressed genes (DEGs) between these subtypes. Based on these DEGs, a prognostic model was constructed using Cox and Lasso regression. The effectiveness, accuracy, and clinical utility of this prognostic model were assessed using numerous independent validation cohorts, survival analyses, receiver operating characteristic (ROC) curves, multivariate Cox regression analysis, nomograms, and calibration curves. Moreover, functional analysis, immune cell infiltration, and drug sensitivity analysis were performed. RESULTS DLBCL patients with different clinical characterizations (age, molecular subtypes, ECOG scores, and stages) showed different expression features of autophagy-related genes. The prediction model was constructed based on the eight autophagy-related genes (ADD3, IGFBP3, TPM1, LYZ, AFDN, DNAJC10, GLIS3, and CCDC102A). The prognostic nomogram for overall survival of DLBCL patients incorporated risk level, stage, ECOG scores, and molecular subtypes, showing excellent agreement between observed and predicted outcomes. Differences were noted in the proportions of immune cells (native B cells, Treg cells, CD8+ T cell, CD4+ memory activated T cells, gamma delta T cells, macrophages M1, and resting mast cells) between high-risk and low-risk groups. LYZ and ADD3 exhibited correlations with drug resistance to most chemotherapeutic drugs. CONCLUSIONS This study established a novel prognostic assessment model based on the expression profile of autophagy-related genes and clinical characteristics of DLBCL patients, explored immune infiltration and predicted drug resistance, which may guide precise and individualized immunochemotherapy regimens.
Collapse
Affiliation(s)
- Dan Xiong
- Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
- Department of Hematology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan 528308, Guangdong, China
| | - Xiaolei Wei
- Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
| | - Weiming Huang
- Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
| | - Jingxia Zheng
- Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
| | - Ru Feng
- Department of Hematology, Nanfang Hospital, Southern Medical University or the First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
6
|
Li X, Zhang Z, Chen L, Zhang J, Chen W, Feng R, Wang X. Multifunctional MnFe 2O 4/TiO 2/Ti 3C 2T x composites based on in-situ grown TiO 2 for efficient microwave absorption, high hydrophobicity, and heat dissipation properties. J Colloid Interface Sci 2024; 654:96-106. [PMID: 37837855 DOI: 10.1016/j.jcis.2023.10.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/11/2023] [Accepted: 10/04/2023] [Indexed: 10/16/2023]
Abstract
Despite the fact that the 2D structure Ti3C2Tx with abundant defects and functional groups contributes to the high microwave absorption (MA) performance, it is difficulty to improve the strength and bandwidth by pursuing higher conductivity or loading more groups due to the limitation of intrinsic properties. Therefore, it is important to ingeniously design efficient Ti3C2Tx based MA composites assembling the features of abundant surface groups, good dispersibility, multiple composition, and precise structure. Inspired by the fact that Ti3C2Tx contains thermodynamically metastable marginal Ti atoms, TiO2 nanoparticles can be grown in-situ on Ti3C2Tx nanosheets uniformly and increase the spacing of Ti3C2Tx layers, and then MnFe2O4 nanoparticles are introduced into the layers of Ti3C2Tx by electrostatic self-assembly method for optimized impedance matching. This designed hierarchical MnFe2O4/TiO2/Ti3C2Tx composites shows excellent MA performance, and the minimum reflection loss (RLmin) reaches -46.91 dB with a thickness of 2.5 mm at frequency of 10.4 GHz. The high MA performance mainly comes from the enhanced interfacial polarization induced by edges location and interface region among TiO2, MnFe2O4, and Ti3C2Tx. In addition, the conduction loss existed in the interior untreated Ti3C2Tx, the dielectric loss generated by multiple composition, the multiple scattering from improved large surface specific area all contribute to the excellent MA performance. Meanwhile, the simple preparation process and good stability storage at room temperature under air atmosphere of the MnFe2O4/TiO2/Ti3C2Tx composites promote its exploration on practical use, and the lab-gown cloth coated with MnFe2O4/TiO2/Ti3C2Tx composites shows better electromagnetic shielding properties, hydrophobicity, and heat transfer ability than pure fabric, showing the potential for practical application.
Collapse
Affiliation(s)
- Xing Li
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Zhaozuo Zhang
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Lin Chen
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Jinming Zhang
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Wansong Chen
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Ru Feng
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| | - Xiaoxia Wang
- College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China.
| |
Collapse
|
7
|
Cai L, Chen H, Wei Y, Guo X, Zheng H, Jiang X, Zhang Y, Yu G, Dai M, Ye J, Zhou H, Xu D, Huang F, Fan Z, Xu N, Shi P, Xuan L, Feng R, Liu X, Sun J, Liu Q, Wei X. Changing epidemiology, microbiology and mortality of bloodstream infections in patients with haematological malignancies before and during SARS-CoV-2 pandemic: a retrospective cohort study. BMJ Open 2023; 13:e078510. [PMID: 38159939 PMCID: PMC10759088 DOI: 10.1136/bmjopen-2023-078510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 11/30/2023] [Indexed: 01/03/2024] Open
Abstract
OBJECTIVE This study was to explore the changes in bacterial bloodstream infection (BSI) in patients with haematological malignancies (HMs) before and during SARS-CoV-2 pandemic. DESIGN Retrospective cohort study between 2018 and 2021. SETTING The largest haematological centre in southern China. RESULTS A total of 599 episodes of BSI occurring in 22 717 inpatients from January 2018 to December 2021 were analysed. The frequencies of the total, Gram-negative and Gram-positive BSI before and during the pandemic were 2.90% versus 2.35% (p=0.011), 2.49% versus 1.77% (p<0.001) and 0.27% versus 0.44% (p=0.027), respectively. The main isolates from Gram-negative or Gram-positive BSI and susceptibility profiles also changed. The 30-day mortality caused by BSI was lower during the pandemic (21.1% vs 14.3%, p=0.043). Multivariate analysis revealed that disease status, pulmonary infection and shock were independent predictors of 30-day mortality. CONCLUSION Our data showed that the incidence of total and Gram-negative organisms BSI decreased, but Gram-positive BSI incidence increased in patients with HMs during the pandemic along with the changes of main isolates and susceptibility profiles. Although the 30-day mortality due to BSI was lower during the pandemic, the new infection prevention strategy should be considered for any future pandemics.
Collapse
Affiliation(s)
- Linjing Cai
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Huan Chen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Yongqiang Wei
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Xutao Guo
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Haiqing Zheng
- Nosocomial Infection Management, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Xuejie Jiang
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Yu Zhang
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Guopan Yu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Min Dai
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Jieyu Ye
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Hongsheng Zhou
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Dan Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Fen Huang
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Zhiping Fan
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Na Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Pengcheng Shi
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Li Xuan
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Ru Feng
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Xiaoli Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Jing Sun
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Qifa Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| | - Xiaolei Wei
- Department of Hematology, Nanfang Hospital, Southern Medical University, Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China
| |
Collapse
|
8
|
Yun X, Bai J, Feng R, Li J, Wang T, Yang Y, Yin J, Qian L, Zhang S, Cao Q, Xue X, Jing H, Liu H. Validation and modification of simplified Geriatric Assessment and Elderly Prognostic Index: Effective tools for older patients with diffuse large B-cell lymphoma. Cancer Med 2023; 13:e6856. [PMID: 38132832 PMCID: PMC10807600 DOI: 10.1002/cam4.6856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Revised: 11/29/2023] [Accepted: 12/10/2023] [Indexed: 12/23/2023] Open
Abstract
Geriatric assessment can aid in optimizing treatment strategies and supportive interventions for older patients with diffuse large B-cell lymphoma (DLBCL). Fondazione Italiana Linformi has recently introduced novel geriatric assessment tools, simplified Geriatric Assessment (sGA) and Elderly Prognostic Index (EPI), aimed at tailoring the treatment and predicting the outcomes for older patients with DLBCL. The objectives of this study are the validation and possible modification of the sGA and EPI in China. In the study, both sGA and EPI demonstrated the predictive capabilities for overall survival (OS) and early mortality (both p < 0.05) in older individuals with DLBCL. Albumin, serving as an independent predictive biomarker for OS (p = 0.006), was utilized to adjust the measurements, resulting in the establishment of sGA-A and EPI-A. The sGA-A effectively addressed the shortcomings of the sGA and EPI in predicting PFS and surpassed them in predicting OS and early mortality. Nevertheless, there is insufficient evidence to support the use of sGA and EPI as treatment guidance tools. In conclusion, the modified sGA-A model proved to be a successful instrument for geriatric assessment of older patients with DLBCL.
Collapse
Affiliation(s)
- Xiaoya Yun
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical SciencesBeijingChina
| | - Jiefei Bai
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Jiangtao Li
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Ting Wang
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Yazi Yang
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Jingjing Yin
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Long Qian
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Shuai Zhang
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Qingyun Cao
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Xiaoxuan Xue
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
| | - Hongmei Jing
- Department of Hematology, Lymphoma Research CenterPeking University Third Hospital, Peking UniversityBeijingChina
| | - Hui Liu
- Department of Hematology, Beijing Hospital, National Center of GerontologyInstitute of Geriatric Medicine, Chinese Academy of Medical SciencesBeijingP.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical SciencesBeijingChina
| |
Collapse
|
9
|
Feng R, Chen Z, Wang Y, Pan J, Shimizu S. Facile Synthesis of Asymmetric aza-Boron Dipyrromethene Analogues Bearing Quinoxaline Moiety. Molecules 2023; 28:7940. [PMID: 38138430 PMCID: PMC10745853 DOI: 10.3390/molecules28247940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Revised: 11/02/2023] [Accepted: 11/17/2023] [Indexed: 12/24/2023] Open
Abstract
An asymmetric aza-BODIPY analogue bearing quinoxaline moiety was synthesized via a titanium tetrachloride-mediated Schiff-base-forming reaction of 6,7-dimethyl-1,4-dihydroquinoxaline-2,3-dione and benzo[d]thiazol-2-amine. This novel aza-BODIPY analogue forms a complementary hydrogen-bonded dimer due to the quinoxaline moiety in the crystal structure. It also shows intense absorption and fluorescence, with fluorescence quantum yields close to unity. The electrochemical measurements and the DFT calculations revealed the presence of the low-lying HOMO, which benefits their potential applications as an electron-transporting material.
Collapse
Affiliation(s)
- Ru Feng
- School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China; (R.F.); (Z.C.); (Y.W.)
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Fukuoka 819-0395, Japan
- Jiangsu Chunlan Clean Energy Academy Co., Ltd., Taizhou 225300, China
| | - Zuoxu Chen
- School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China; (R.F.); (Z.C.); (Y.W.)
| | - Yue Wang
- School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China; (R.F.); (Z.C.); (Y.W.)
- Jiangsu Agrochem Laboratory Co., Ltd., Changzhou 213022, China
| | - Jianming Pan
- School of Chemistry and Chemical Engineering, Jiangsu University, Zhenjiang 212013, China; (R.F.); (Z.C.); (Y.W.)
| | - Soji Shimizu
- Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Fukuoka 819-0395, Japan
- Center for Molecular Systems (CMS), Kyushu University, Fukuoka 819-0395, Japan
| |
Collapse
|
10
|
Feng R, Zhang S, Li JT, Wang T, Zhang CL, Bai JF, Yang L, Wang LR, Jing HM, Liu H. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment. Ther Adv Hematol 2023; 14:20406207231208979. [PMID: 38033755 PMCID: PMC10685783 DOI: 10.1177/20406207231208979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 09/29/2023] [Indexed: 12/02/2023] Open
Abstract
Background The outcome of patients with acute myeloid leukemia (AML) aged ⩾65 years is poor. Effective treatment options are limited for patients with AML who cannot tolerate intensive chemotherapy. Objectives We aimed to evaluate the efficacy of low-dose decitabine in previously untreated patients with AML aged ⩾65 years who were ineligible for intensive chemotherapy based on a comprehensive geriatric assessment. Design We performed a prospective, multicenter, open-label, and non-randomized study. Methods Patients were enrolled at four centers in Beijing between 1 January 2017 and 31 December 2020. They were treated with decitabine at a dose of 6 mg/m2 for 10 days. The treatment was repeated every 28 days for one cycle for a total of six cycles. The primary endpoint of our study was overall survival (OS) at the end of the first year after enrolment. The secondary endpoints included overall response rate, leukemia-free survival, relapse rate, treatment-related mortality (TRM), quality of life, safety, and transfusion dependence. Patients were continuously monitored for toxicity. Results Overall, 47 patients (30 males and 17 females) participated in this study. The median age of the enrolled patients was 78 (range, 65-90) years. The median follow-up time was 22.2 (range, 4.6-38.8) months. Fifteen (31.9%) patients achieved complete remission (CR), 11 (23.4%) patients achieved partial remission, 3 (6.4%) patients achieved hematological improvement only, and 18 (38.3%) patients did not achieve remission. The median time to obtain CR was 2 months. The median CR was 8.5 months. Of the patients, 36 (76.6%) patients completed six cycles of treatment with low-dose decitabine, and the 1-year OS was 36.1%. According to instrumental activities of daily living scales, age, comorbidities, and albumin (IACA) scores, the median survival was 11.2 months in the unfit group and 6 months in the frail group. The 1-year OS rates in the unfit and frail groups were 49.2% and 23.4%, respectively. Grade ⩾3 non-hematological toxicity was observed in 70.2% (33/47) of the patients. TRM occurred in three patients. No early deaths occurred after treatment. Conclusion In newly diagnosed older patients with AML whose IACA assessment was unfit or frail for standard chemotherapy, treatment with low-dose decitabine demonstrated clinical activity and good security in our study.
Collapse
Affiliation(s)
- Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Shuai Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Jiang-Tao Li
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Ting Wang
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Chun-Li Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Jie-Fei Bai
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Lei Yang
- Department of Hematology, Beijing Tongren Hospital, Beijing, China
| | - Li-Ru Wang
- Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing, China
| | - Hong-Mei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China No. 1 DaHua Road, Dong Dan, Beijing 100730, China
| |
Collapse
|
11
|
Li A, Feng R. [CAR-T cell therapy-related long-term cytopenias]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:870-875. [PMID: 38049346 PMCID: PMC10694071 DOI: 10.3760/cma.j.issn.0253-2727.2023.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Indexed: 12/06/2023]
Affiliation(s)
- A Li
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - R Feng
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| |
Collapse
|
12
|
Guo Q, Liu J, Dou X, Zhu K, Shi P, Zhang Y, Li S, Feng R, Yue J. Camrelizumab with Chemoradiotherapy for Locally Advanced Biliary Tract Cancer: Preliminary Results from A Phase II Study. Int J Radiat Oncol Biol Phys 2023; 117:e355. [PMID: 37785226 DOI: 10.1016/j.ijrobp.2023.06.2434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) For locally advanced biliary tract cancer (BTC), capecitabine-based chemoradiotherapy (CRT) is commonly used but has limited benefits. Immunotherapy is potentially effective for BTC and may be synergized with CRT. Followed by gemcitabine and cisplatin (GP) consolidation chemotherapy (CT), we evaluated the safety and efficacy of combined camrelizumab and capecitabine-based CRT for locally advanced BTC. MATERIALS/METHODS Patients had stage II-III (T4N0M0, T1-4N+M0) BTC (per the 7th [2010] edition of the American Joint Committee on Cancer staging system) were eligible for CRT (capecitabine plus [50-60 Gy] radiotherapy), to be followed by GP CT. Camrelizumab was given concurrently with CRT. Safety was defined as the incidence and severity of adverse events (AEs), while efficacy was defined as overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR). RESULTS Ten patients completed the planned treatment. None experienced grade ≥3 treatment-related AEs during CRT. Grade ≥3 immune-related AEs occurred in 2 of 10 patients (20%) only during GP CT. The mean OS time was 18.2 months (95% confidence interval [CI] 12.9m-23.5m) while the median OS time was 14.1 months (95% CI 10.1m-18.1m). OS rates were 100%, 59%, 44% at 6 months, 1 year and 2 years, respectively. The ORR was 30% while the DCR was 90%. Two patients (20%) obtained OS over 2 years with partial response (25.9m, 29.1m). Median PFS time was 14.1 months (95% CI 9.3m-18.9m). CONCLUSION Camrelizumab in combination with concurrent CRT was well tolerated and did not impair delivery of CRT in patients with locally advanced BTC.
Collapse
Affiliation(s)
- Q Guo
- Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - J Liu
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - X Dou
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - K Zhu
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - P Shi
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Y Zhang
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - S Li
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - R Feng
- Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - J Yue
- Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China; Shandong Cancer Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China
| |
Collapse
|
13
|
An ZY, Wu YJ, Hou Y, Mei H, Nong WX, Li WQ, Zhou H, Feng R, Shen JP, Peng J, Zhou H, Liu Y, Song YP, Yang LH, Fang MY, Li JY, Cheng YF, Liu P, Xu YJ, Wang Z, Luo Y, Cai Z, Liu H, Wang JW, Li J, Zhang X, Sun ZM, Zhu XY, Wang X, Fu R, Huang L, Wang SY, Yang TH, Su LP, Ma LM, Chen XQ, Liu DH, Yao HX, Feng J, Zhang HY, Jiang M, Zhou ZP, Wang WS, Shen XL, Baima Y, Li YY, Wang QF, Huang QS, Fu HX, Zhu XL, He Y, Jiang Q, Jiang H, Lu J, Zhao XY, Chang YJ, Wu T, Pan YZ, Qiu L, Gao D, Jin AR, Li W, Gao SJ, Zhang L, Hou M, Huang XJ, Zhang XH. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Sci Bull (Beijing) 2023; 68:2106-2114. [PMID: 37599175 DOI: 10.1016/j.scib.2023.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 02/24/2023] [Accepted: 06/26/2023] [Indexed: 08/22/2023]
Abstract
Rare but critical bleeding events in primary immune thrombocytopenia (ITP) present life-threatening complications in patients with ITP, which severely affect their prognosis, quality of life, and treatment decisions. Although several studies have investigated the risk factors related to critical bleeding in ITP, large sample size data, consistent definitions, large-scale multicenter findings, and prediction models for critical bleeding events in patients with ITP are unavailable. For the first time, in this study, we applied the newly proposed critical ITP bleeding criteria by the International Society on Thrombosis and Hemostasis for large sample size data and developed the first machine learning (ML)-based online application for predict critical ITP bleeding. In this research, we developed and externally tested an ML-based model for determining the risk of critical bleeding events in patients with ITP using large multicenter data across China. Retrospective data from 8 medical centers across the country were obtained for model development and prospectively tested in 39 medical centers across the country over a year. This system exhibited good predictive capabilities for training, validation, and test datasets. This convenient web-based tool based on a novel algorithm can rapidly identify the bleeding risk profile of patients with ITP and facilitate clinical decision-making and reduce the occurrence of adversities.
Collapse
Affiliation(s)
- Zhuo-Yu An
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Ye-Jun Wu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Yu Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250014, China
| | - Heng Mei
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Wei-Xia Nong
- Department of Hematology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi 832002, China
| | - Wen-Qian Li
- Department of Hematology, Qinghai Provincial People's Hospital, Xining 810007, China
| | - Hu Zhou
- Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan Institute of Hematology, Zhengzhou 450008, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, Beijing 100044, China
| | - Jian-Ping Shen
- Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310006, China
| | - Jun Peng
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250014, China
| | - Hai Zhou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250014, China
| | - Yi Liu
- Department of Hematology, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing 100044, China
| | - Yong-Ping Song
- Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Henan Institute of Hematology, Zhengzhou 450008, China
| | - Lin-Hua Yang
- Department of Hematology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China
| | - Mei-Yun Fang
- Department of Hematology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China
| | - Jian-Yong Li
- Department of Hematology, The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing 210029, China
| | - Yun-Feng Cheng
- Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - Peng Liu
- Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008, China
| | - Ya-Jing Xu
- Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100044, China
| | - Zhao Wang
- Institute of Hematology, the First Affiliated Hospital, Zhejiang University, Hangzhou 310058, China
| | - Yi Luo
- Department of Hematology, Beijing Tongren Hospital, Beijing 100005, China
| | - Zhen Cai
- Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, Beijing 100044, China
| | - Jing-Wen Wang
- Department of Hematology, Beijing Tongren Hospital, Beijing 100005, China
| | - Juan Li
- Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
| | - Xi Zhang
- Medical Center of Hematology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China
| | - Zi-Min Sun
- Department of Hematology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Xiao-Yu Zhu
- Department of Hematology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
| | - Xin Wang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250014, China
| | - Rong Fu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - Liang Huang
- Institute of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China
| | - Shao-Yuan Wang
- Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Tong-Hua Yang
- Department of Hematology, the First People's Hospital of Yunnan Province, Kunming 650032, China
| | - Li-Ping Su
- Department of Hematology, Shanxi Tumor Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, China
| | - Liang-Ming Ma
- Department of Hematology, Shanxi Bethune Hospital of Shanxi Medical University, Taiyuan 030001, China
| | - Xie-Qun Chen
- Department of Hematology, The Affiliated Hospital of Northwest Hospital, Xi'an No.3 Hospital, Xi'an 710054, China
| | - Dai-Hong Liu
- Department of Hematology, Chinese PLA General Hospital & PLA Medical School, Beijing 100044, China
| | - Hong-Xia Yao
- Department of Hematology, Hainan Affiliated Hospital of Hainan Medical University, Hainan General Hospital, Haikou 570311, China
| | - Jia Feng
- Department of Hematology, Peking University Shenzhen Hospital, Shenzhen 518036, China
| | - Hong-Yu Zhang
- Department of Hematology, Peking University Shenzhen Hospital, Shenzhen 518036, China
| | - Ming Jiang
- Center of Hematologic Diseases, The First Affiliated Hospital of Xinjiang Medical University, Urumchi 830054, China
| | - Ze-Ping Zhou
- Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650500, China
| | - Wen-Sheng Wang
- Department of Hematology, Peking University First Hospital, Beijing 100034, China
| | - Xu-Liang Shen
- Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China
| | - Yangjin Baima
- Department of Hematology, People's Hospital of Tibet Autonomous Region, Lhasa 850000, China
| | - Yue-Ying Li
- Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100029, China
| | - Qian-Fei Wang
- Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100029, China
| | - Qiu-Sha Huang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Hai-Xia Fu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Xiao-Lu Zhu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Yun He
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Qian Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Hao Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Jin Lu
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Xiang-Yu Zhao
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Ying-Jun Chang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China
| | - Tao Wu
- Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou 730050, China
| | - Yao-Zhu Pan
- Department of Hematology, The 940th Hospital of Joint Logistics Support Force of Chinese PLA, Lanzhou 730050, China
| | - Lin Qiu
- Institute of Hematology, Harbin the First Hospital, Harbin 150001, China
| | - Da Gao
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
| | - A-Rong Jin
- Department of Hematology, Inner Mongolia People's Hospital, Hohhot 010017, China
| | - Wei Li
- Department of Hematology, The First Bethune Hospital of Jilin University, Changchun 130021, China
| | - Su-Jun Gao
- Department of Hematology, The First Bethune Hospital of Jilin University, Changchun 130021, China
| | - Lei Zhang
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
| | - Ming Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250014, China.
| | - Xiao-Jun Huang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
| | - Xiao-Hui Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China; Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
| |
Collapse
|
14
|
Ouyang S, Zhai Y, Feng R, Xiong Y, Yu L, Liu C. [A close contact of coronavirus disease 2019 with severe imported malaria: a case report]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi 2023; 35:421-423. [PMID: 37926480 DOI: 10.16250/j.32.1374.2022271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/07/2023]
Abstract
This article presents a severe cerebral malaria patient in shock with a close contact of COVID-19 that was successfully cured in a negative pressure ward during the global pandemic of COVID-19. The patient experienced a sudden onset of high fever and coma in a designated isolation hotel after returning from Africa, and was transferred to a designated hospital. Following antimalarial therapy, blood pressure elevation, increase of blood volume, bedside hemodialysis, mechanical ventilation, plasma and platelet transfusions, the case gradual recovered.
Collapse
Affiliation(s)
- S Ouyang
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
| | - Y Zhai
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
| | - R Feng
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
| | - Y Xiong
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
| | - L Yu
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
- North China University of Technology School of Public Health, Tangshan, Hebei 063210, China
| | - C Liu
- The Fifth Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, Guangzhou, Guangdong 510700, China
| |
Collapse
|
15
|
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J. Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis. Cancer Med 2023; 12:18643-18653. [PMID: 37705497 PMCID: PMC10557885 DOI: 10.1002/cam4.6473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 07/24/2023] [Accepted: 08/14/2023] [Indexed: 09/15/2023] Open
Abstract
BACKGROUND We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second-line versus later-line. Here, we present an updated pooled analysis with a longer follow-up of 35.2 months. METHODS Data were pooled from two studies-BGB-3111-AU-003 (NCT02343120) and BGB-3111-206 (NCT03206970) of zanubrutinib in R/R MCL. The patients were divided into two groups based on the treatment line of zanubrutinib: the second-line and the later-line group. The inverse propensity score weighting method was used to balance the baseline covariates between the groups. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), PFS, and OS rates, objective response rate (ORR), duration of response (DOR), and safety. RESULTS Among 112 pooled patients, 41 (36.6%) patients received zanubrutinib as second-line and 71 (63.4%) patients as later-line therapy. After weighting, OS was significantly improved in the second-line versus later-line group (HR, 0.459 [95% CI: 0.215, 0.98]; p = 0.044) with median OS not estimable in both groups. The PFS was similar between the two groups (HR, 0.78 [95% CI: 0.443, 1.373]; p = 0.389) but with numerically longer median PFS in the second-line versus later-line group (27.8 vs. 22.1 months). ORR was numerically higher in the second-line versus later-line (88.6% vs. 85.7%), and DOR was similar between the two groups (25.2 vs. 25.1 months). Zanubrutinib showed a similar safety profile in both groups. CONCLUSION Zanubrutinib in second-line treatment was associated with significantly improved OS compared with later-line treatment of R/R MCL.
Collapse
Affiliation(s)
- Yuqin Song
- Peking University Cancer Hospital and InstituteBeijingChina
| | - Keshu Zhou
- Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouChina
| | - Dehui Zou
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeTianjinChina
| | - Dengju Li
- Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
| | - Jianda Hu
- Fujian Medical University Union HospitalFuzhouChina
| | - Haiyan Yang
- The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of SciencesHangzhouChina
| | - Huilai Zhang
- Tianjin Medical University Cancer Institute and HospitalTianjinChina
| | - Jie Ji
- West China Hospital of Sichuan UniversityChengduChina
| | - Wei Xu
- The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalNanjingChina
| | - Jie Jin
- The First Affiliated HospitalZhejiang University College of MedicineHangzhouChina
| | - Fangfang Lv
- Fudan University Shanghai Cancer CenterShanghaiChina
| | - Ru Feng
- Nanfang Hospital of Southern Medical UniversityGuangzhouChina
| | - Sujun Gao
- The First Hospital of Jilin UniversityChangchunChina
| | - Daobin Zhou
- Peking Union Medical College HospitalChinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
| | - Constantine S. Tam
- Peter MacCallum Cancer Centre, St. Vincent's HospitalUniversity of MelbourneMelbourneVictoriaAustralia
| | | | - Michael Wang
- The University of Texas MD Anderson Cancer CenterHoustonTexasUSA
| | | | - Stephen Opat
- Monash Health, Monash UniversityClaytonVictoriaAustralia
| | | | | | - Jun Zhu
- Peking University Cancer Hospital and InstituteBeijingChina
| |
Collapse
|
16
|
Lambert H, Shen X, Chai J, Cheng J, Feng R, Chen M, Cabral C, Oliver I, Shen J, MacGowan A, Bowker K, Hickman M, Kadetz P, Zhao L, Pan Y, Kwiatkowska R, Hu X, Wang D. Prevalence, drivers and surveillance of antibiotic resistance and antibiotic use in rural China: Interdisciplinary study. PLOS Glob Public Health 2023; 3:e0001232. [PMID: 37556412 PMCID: PMC10411760 DOI: 10.1371/journal.pgph.0001232] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Accepted: 05/22/2023] [Indexed: 08/11/2023]
Abstract
This study aimed to characterise antibiotic prescribing and dispensing patterns in rural health facilities in China and determine the community prevalence of antibiotic resistance. We investigated patterns and drivers of antibiotic use for common respiratory and urinary tract infections (RTI/UTI) in community settings, examined relationships between presenting symptoms, clinical diagnosis and microbiological results in rural outpatient clinics, and assessed potential for using patient records to monitor antibiotic use. This interdisciplinary mixed methods study included: (i) Observations and exit interviews in eight village clinics and township health centres and 15 retail pharmacies; (ii) Urine, throat swab and sputum samples from patients to identify potential pathogens and test susceptibility; (iii) 103 semi-structured interviews with doctors, patients, pharmacy workers and antibiotic-purchasing customers; (iv) Assessment of completeness and accuracy of electronic patient records through comparison with observational data. 87.9% of 1123 recruited clinic patients were prescribed antibiotics (of which 35.5% contained antibiotic combinations and >40% were for intravenous administration), most of whom had RTIs. Antibiotic prescribing for RTIs was not associated with presence of bacterial pathogens but was correlated with longer duration of infection (OR = 3.33) and presence of sore throat (OR = 1.64). Fever strongly predicted prescription of intravenous antibiotics (OR = 2.87). Resistance rates in bacterial pathogens isolated were low compared with national data. 25.8% of patients reported antibiotics use prior to their clinic visit, but only 56.2% of clinic patients and 53% of pharmacy customers could confirm their prescription or purchase included antibiotics. Diagnostic uncertainty, financial incentives, understanding of antibiotics as anti-inflammatory and limited doctor-patient communication were identified as key drivers of antibiotic use. Completion and accuracy of electronic patient records were highly variable. Prevalence of antibiotic resistance in this rural population is relatively low despite high levels of antibiotic prescribing and self-medication. More systematic use of e-records and in-service training could improve antibiotic surveillance and stewardship in rural facilities. Combining qualitative and observational anthropological methods and concepts with microbiological and epidemiological investigation of antibiotic resistance at both research design and analytic synthesis stages substantially increases the validity of research findings and their utility in informing future intervention development.
Collapse
Affiliation(s)
- H. Lambert
- Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - X. Shen
- School of Health Services Management, Anhui Medical University, Hefei, China
| | - J. Chai
- School of Health Services Management, Anhui Medical University, Hefei, China
| | - J. Cheng
- School of Health Services Management, Anhui Medical University, Hefei, China
| | - R. Feng
- Library Department of Literature Retrieval and Analysis, Anhui Medical University, Hefei, China
| | - M. Chen
- Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - C. Cabral
- Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - I. Oliver
- Field Service, National Infection Service, UK Health Security Agency, Bristol, United Kingdom
| | - J. Shen
- Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
| | - A. MacGowan
- Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom
| | - K. Bowker
- Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom
| | - M. Hickman
- Bristol Medical School, University of Bristol, Bristol, United Kingdom
| | - P. Kadetz
- Institute for Global Health and Development, Queen Margaret University, Edinburgh, United Kingdom
| | - L. Zhao
- School of Health Services Management, Anhui Medical University, Hefei, China
| | - Y. Pan
- First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - R. Kwiatkowska
- Field Service, National Infection Service, UK Health Security Agency, Bristol, United Kingdom
| | - X. Hu
- Anhui Provincial Hospital, Hefei, China
| | - D. Wang
- School of Health Services Management, Anhui Medical University, Hefei, China
| |
Collapse
|
17
|
Song Y, Zhou K, Yang S, Hu J, Zou D, Gao S, Pan L, Wang T, Yang H, Zhang H, Zhou D, Ji J, Xu W, Feng R, Jin J, Lv F, Huang H, Fan X, Xu S, Zhu J. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Invest New Drugs 2023; 41:606-616. [PMID: 37420136 PMCID: PMC10447591 DOI: 10.1007/s10637-023-01376-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 06/02/2023] [Indexed: 07/09/2023]
Abstract
We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or R/R mantle cell lymphoma (MCL). An unanchored matching-adjusted indirect comparison (MAIC) was performed in R/R CLL/SLL patients. Individual patient data from zanubrutinib trial (BGB-3111-205) were adjusted to match the aggregated data from the orelabrutinib trial (ICP-CL-00103). A naïve comparison was performed in R/R MCL for the different response assessment methodology and efficacy analysis set between the zanubrutinib (BGB-3111-206) and orelabrutinib (ICP-CL-00102) trials. Efficacy outcomes included ORR and PFS. In R/R CLL/SLL patients, after matching, IRC-assessed ORR was comparable (86.6% vs. 92.5%; risk difference, -5.9% [95% CI: -15.8%-3.8%]); IRC-assessed PFS was similar with a favorable trend in zanubrutinib over orelabrutinib (HR, 0.74 [95% CI: 0.37-1.47]) and the 18-month PFS rate was numerically higher in zanubrutinib (82.9% vs. 78.7%). In R/R MCL patients, naïve comparison showed investigator-assessed ORR was similar (83.7% vs. 87.9%; risk difference, -4.2% [95% CI: -14.8%-6.0%]), and CR rate was significantly higher in zanubrutinib over orelabrutinib (77.9% vs. 42.9%; risk difference, 35.0% [95% CI: 14.5%, 53.7%]). Investigator-assessed PFS was similar with a favorable trend (HR, 0.77 [95% CI: 0.45-1.32]) in zanubrutinib over orelabrutinib and the 12-month PFS rate was numerically higher in zanubrutinib (77.5% vs. 70.8%). MAIC result showed zanubrutinib demonstrated favorable PFS over orelabrutinib for R/R CLL/SLL patients. The naïve comparison showed zanubrutinib had favorable PFS and higher CR rate than orelabrutinib for R/R MCL patients.
Collapse
Affiliation(s)
- Yuqin Song
- Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), No. 52 Fucheng Road, Haidian District, Beijing, 100142 China
| | - Keshu Zhou
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Shenmiao Yang
- Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
| | - Jianda Hu
- Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Dehui Zou
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Sujun Gao
- Department of Hematology of Cancer Center, The First Hospital of Jilin University, Changchun, China
| | - Ling Pan
- Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
| | - Tingyu Wang
- State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Haiyan Yang
- Department of Lymphoma, The Cancer Hospitalof the, University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
| | - Huilai Zhang
- Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
| | - Daobin Zhou
- Department of Hematology, Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, PekingBeijing, China
| | - Jie Ji
- Department of Hematology, West China Hospital of Sichuan University, Chengdu, China
| | - Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
| | - Ru Feng
- Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, China
| | - Jie Jin
- Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China
| | - Fangfang Lv
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - Haiwen Huang
- Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Xiaosi Fan
- BeiGene (Beijing) Co., Ltd, Beijing, China
| | - Sheng Xu
- BeiGene (Beijing) Co., Ltd, Beijing, China
| | - Jun Zhu
- Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), No. 52 Fucheng Road, Haidian District, Beijing, 100142 China
| |
Collapse
|
18
|
Zhuo Z, Wang Q, Li C, Zhang L, Zhang L, You R, Gong Y, Hua Y, Miao L, Bai J, Zhang C, Feng R, Chen M, Su F, Qu C, Xiao F. IGH rod-like tracer: An AlphaFold2 structural similarity extraction-based predictive biomarker for MRD monitoring in pre-B-ALL. iScience 2023; 26:107107. [PMID: 37408685 PMCID: PMC10319212 DOI: 10.1016/j.isci.2023.107107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 05/31/2023] [Accepted: 06/08/2023] [Indexed: 07/07/2023] Open
Abstract
Sequence variation resulting from the evolution of IGH clones and immunophenotypic drift makes it difficult to track abnormal B cells in children with precursor B cell acute lymphoblastic leukemia (pre-B-ALL) by flow cytometry, qPCR, or next-generation sequencing (NGS). The V-(D)-J regions of immunoglobulin and T cell receptor of 47 pre-B-ALL samples were sequenced using the Illumina NovaSeq platform. The IGH rod-like tracer consensus sequence was extracted based on its rod-like alpha-helices structural similarity predicted by AlphaFold2. Additional data from published 203 pre-B-ALL samples were applied for validation. NGS-IGH (+) patients with pre-B-ALL had a poor prognosis. Consistent CDR3-coded protein structures in NGS-IGH (+) samples could be extracted as a potential follow-up marker for pre-B-ALL children during treatment. IGH rod-like tracer from quantitative immune repertoire sequencing may serve as a class of biomarker with significant predictive values for the dynamic monitoring of MRD in pre-B-ALL children.
Collapse
Affiliation(s)
- Zhongling Zhuo
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
- Department of Laboratory Medicine, Peking University People’s Hospital, Beijing, China
| | - Qingchen Wang
- Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
| | - Chang Li
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Lili Zhang
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Lanxin Zhang
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Ran You
- Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
| | - Yan Gong
- Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
| | - Ying Hua
- Department of Pediatrics, Peking University First Hospital, Beijing, China
| | - Linzi Miao
- Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
| | - Jiefei Bai
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Chunli Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Meng Chen
- National Cancer Data Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China
| | - Fei Su
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Chenxue Qu
- Department of Clinical Laboratory, Peking University First Hospital, Beijing, China
| | - Fei Xiao
- Clinical Biobank, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, National Health Commission, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
19
|
Li X, An S, Luo Z, Zhou P, Wang L, Feng R. Polysaccharides from the hard shells of Juglans regia L. modulate intestinal function and gut microbiota in vivo. Food Chem 2023; 412:135592. [PMID: 36736188 DOI: 10.1016/j.foodchem.2023.135592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 12/25/2022] [Accepted: 01/26/2023] [Indexed: 01/31/2023]
Abstract
This study aimed to investigate the modulatory effects of polysaccharides from the hard shells ofJuglans regiaL. (JRP) on intestinal function and gut microbiota of mice. The results showed that JRP could increase the colonic length and colonic index, and ameliorate the histological characteristics of colon. JRP had a positive effect on immunity of mice by improving immune organ indexes. Owing to enhancement of intestinal peristalsis and increase of colonic fecal moisture by JRP, the defecation time was significantly reduced. After gastrointestinal digestion and absorption, JRP was metabolized by intestinal microorganisms to produce short chain fatty acids, thereby lowering the pH of intestine. Through microbial community analysis, the composition of gut microbiota was modulated by JRPvia increasing theabundances of beneficial bacteriaand decreasing the richness of harmful bacteria. This study suggests that JRP can be served as an excellent prebiotic to promote intestinal health.
Collapse
Affiliation(s)
- Xiaoyu Li
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China
| | - Siying An
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China
| | - Zhen Luo
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China
| | - Peng Zhou
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China
| | - Lu Wang
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China.
| | - Ru Feng
- Nano-biotechnology Key Laboratory of Hebei Province, Skate Key Laboratory of Metastable Materials Science and Technology, School of Environmental and Chemical Engineering, Yanshan University, Qinhuangdao 066004, PR China
| |
Collapse
|
20
|
Cai LJ, Wei XL, Wei YQ, Guo XT, Jiang XJ, Zhang Y, Yu GP, Dai M, Ye JY, Zhou HS, Xu D, Huang F, Fan ZP, Xu N, Shi PC, Xuan L, Feng R, Liu XL, Sun J, Liu QF. [A single-center study on the distribution and antibiotic resistance of pathogens causing bloodstream infection in patients with hematological malignancies]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:479-483. [PMID: 37550203 PMCID: PMC10450548 DOI: 10.3760/cma.j.issn.0253-2727.2023.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Indexed: 08/09/2023]
Abstract
Objective: To study the incidence of bloodstream infections, pathogen distribution, and antibiotic resistance profile in patients with hematological malignancies. Methods: From January 2018 to December 2021, we retrospectively analyzed the clinical characteristics, pathogen distribution, and antibiotic resistance profiles of patients with malignant hematological diseases and bloodstream infections in the Department of Hematology, Nanfang Hospital, Southern Medical University. Results: A total of 582 incidences of bloodstream infections occurred in 22,717 inpatients. From 2018 to 2021, the incidence rates of bloodstream infections were 2.79%, 2.99%, 2.79%, and 2.02%, respectively. Five hundred ninety-nine types of bacteria were recovered from blood cultures, with 487 (81.3%) gram-negative bacteria, such as Klebsiella pneumonia, Escherichia coli, and Pseudomonas aeruginosa. Eighty-one (13.5%) were gram-positive bacteria, primarily Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecium, whereas the remaining 31 (5.2%) were fungi. Enterobacteriaceae resistance to carbapenems, piperacillin/tazobactam, cefoperazone sodium/sulbactam, and tigecycline were 11.0%, 15.3%, 15.4%, and 3.3%, with a descending trend year on year. Non-fermenters tolerated piperacillin/tazobactam, cefoperazone sodium/sulbactam, and quinolones at 29.6%, 13.3%, and 21.7%, respectively. However, only two gram-positive bacteria isolates were shown to be resistant to glycopeptide antibiotics. Conclusions: Bloodstream pathogens in hematological malignancies were broadly dispersed, most of which were gram-negative bacteria. Antibiotic resistance rates vary greatly between species. Our research serves as a valuable resource for the selection of empirical antibiotics.
Collapse
Affiliation(s)
- L J Cai
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - X L Wei
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - Y Q Wei
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - X T Guo
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - X J Jiang
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - Y Zhang
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - G P Yu
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - M Dai
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - J Y Ye
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - H S Zhou
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - D Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - F Huang
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - Z P Fan
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - N Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - P C Shi
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - L Xuan
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - R Feng
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - X L Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - J Sun
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| | - Q F Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou 510515, China
| |
Collapse
|
21
|
Jin F, Yin H, Feng R, Niu W, Zhang W, Liu J, Du A, Yang W, Liu Z. Charge transfer and vacancy engineering of Fe 2O 3 nanoparticle catalysts for highly selective N 2 reduction towards NH 3 synthesis. J Colloid Interface Sci 2023; 647:354-363. [PMID: 37267798 DOI: 10.1016/j.jcis.2023.05.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 05/11/2023] [Accepted: 05/17/2023] [Indexed: 06/04/2023]
Abstract
The development of electrocatalysts for N2 reduction reaction (NRR) is significant for scalable and renewable NH3 synthesis, but calls for a technology innovation to overcome the specific problems of low efficiency and poor selectivity. Herein, we prepare a core-shell nanostructure by coating polypyrrole (PPy) onto sulfur-doped iron oxide nanoparticles (denoted as S-Fe2O3@PPy) as the highly selective and durable electrocatalysts for NRR under ambient conditions. Sulfur doping and PPy coating remarkably improve the charge transfer efficiency of S-Fe2O3@PPy, and the interactions between PPy and Fe2O3 nanoparticles produce abundant oxygen vacancies as active sites for NRR. This catalyst achieves an NH3 production rate of 22.1 μg h-1 mgcat-1 and a very-high Faradic efficiency of 24.6%, surpassing other Fe2O3 based NRR catalysts. Density functional theory calculations show that the S-coordinated iron site can successfully activate the N2 molecule and optimize the energy barrier during the reduction process, resulting in a small theoretical limiting potential.
Collapse
Affiliation(s)
- Fuhao Jin
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China
| | - Hanqing Yin
- School of Chemistry and Physics and Centre for Materials Science, Queensland University of Technology, Gardens Point Campus, Brisbane, 4001, Australia
| | - Ru Feng
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China
| | - Wei Niu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China
| | - Wanting Zhang
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China
| | - Jingquan Liu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China
| | - Aijun Du
- School of Chemistry and Physics and Centre for Materials Science, Queensland University of Technology, Gardens Point Campus, Brisbane, 4001, Australia
| | - Wenrong Yang
- School of Life and Environmental Sciences, Deakin University, 75 Pigdons Road, Geelong, VIC 3216, Australia
| | - Zhen Liu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao 266071, PR China.
| |
Collapse
|
22
|
Xu W, Yi SH, Feng R, Wang X, Jin J, Mi JQ, Ding KY, Yang W, Niu T, Wang SY, Zhou KS, Peng HL, Huang L, Liu LH, Ma J, Luo J, Su LP, Bai O, Liu L, Li F, He PC, Zeng Y, Gao D, Jiang M, Wang JS, Yao HX, Qiu LG, Li JY. [Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:380-387. [PMID: 37550187 PMCID: PMC10440613 DOI: 10.3760/cma.j.issn.0253-2727.2023.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Indexed: 08/09/2023]
Abstract
Objective: To understand the current status of diagnosis and treatment of chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) among hematologists, oncologists, and lymphoma physicians from hospitals of different levels in China. Methods: This multicenter questionnaire survey was conducted from March 2021 to July 2021 and included 1,000 eligible physicians. A combination of face-to-face interviews and online questionnaire surveys was used. A standardized questionnaire regarding the composition of patients treated for CLL/SLL, disease diagnosis and prognosis evaluation, concomitant diseases, organ function evaluation, treatment selection, and Bruton tyrosine kinase (BTK) inhibitor was used. Results: ①The interviewed physicians stated that the proportion of male patients treated for CLL/SLL is higher than that of females, and the age is mainly concentrated in 61-70 years old. ②Most of the interviewed physicians conducted tests, such as bone marrow biopsies and immunohistochemistry, for patient diagnosis, in addition to the blood test. ③Only 13.7% of the interviewed physicians fully grasped the initial treatment indications recommended by the existing guidelines. ④In terms of cognition of high-risk prognostic factors, physicians' knowledge of unmutated immunoglobulin heavy-chain variable and 11q- is far inferior to that of TP53 mutation and complex karyotype, which are two high-risk prognostic factors, and only 17.1% of the interviewed physicians fully mastered CLL International Prognostic Index scoring system. ⑤Among the first-line treatment strategy, BTK inhibitors are used for different types of patients, and physicians have formed a certain understanding that BTK inhibitors should be preferentially used in patients with high-risk factors and elderly patients, but the actual use of BTK inhibitors in different types of patients is not high (31.6%-46.0%). ⑥BTK inhibitors at a reduced dose in actual clinical treatment were used by 69.0% of the physicians, and 66.8% of the physicians had interrupted the BTK inhibitor for >12 days in actual clinical treatment. The use of BTK inhibitors is reduced or interrupted mainly because of adverse reactions, such as atrial fibrillation, severe bone marrow suppression, hemorrhage, and pulmonary infection, as well as patients' payment capacity and effective disease progression control. ⑦Some differences were found in the perceptions and behaviors of hematologists and oncologists regarding the prognostic assessment of CLL/SLL, the choice of treatment options, the clinical use of BTK inhibitors, etc. Conclusion: At present, a gap remains between the diagnosis and treatment of CLL/SLL among Chinese physicians compared with the recommendations in the guidelines regarding the diagnostic criteria, treatment indications, prognosis assessment, accompanying disease assessment, treatment strategy selection, and rational BTK inhibitor use, especially the proportion of dose reduction or BTK inhibitor discontinuation due to high adverse events.
Collapse
Affiliation(s)
- W Xu
- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| | - S H Yi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - R Feng
- Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - X Wang
- Shandong Provincial Hospital, Jinan 250021, China
| | - J Jin
- The First Affiliated Hospital of Medical College of Zhejiang University, Hangzhou 310003, China
| | - J Q Mi
- Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai 200025, China
| | - K Y Ding
- Anhui Province Cancer Hospital, Hefei 230031, China
| | - W Yang
- Shengjing Hospital Affiliated to China Medical University, Shenyang 117004, China
| | - T Niu
- West China Hospital of Sichuan University, Chengdu 610044, China
| | - S Y Wang
- Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China
| | - K S Zhou
- Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou 450003, China
| | - H L Peng
- Xiangya Second Hospital of Central South University, Changsha 410008, China
| | - L Huang
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
| | - L H Liu
- The Fourth Hospital of Hebei Medical University (Hebei Tumor Hospital), Shijiazhuang 050011, China
| | - J Ma
- Harbin Institute of hematological oncology, Harbin 150001, China
| | - J Luo
- The First Affiliated Hospital of Guangxi Medical University, Nanchang 530021, China
| | - L P Su
- Shanxi Cancer Hospital, Taiyuan 030013, China
| | - O Bai
- The first hospital of Jilin University, Changchun 130061, China
| | - L Liu
- The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, China
| | - F Li
- The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
| | - P C He
- The First Affiliated Hospital of Xi' an Jiaotong University, Xi' an 710061, China
| | - Y Zeng
- The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
| | - D Gao
- Affiliated Hospital of Inner Mongolia Medical University, Hohhot 750306, China
| | - M Jiang
- The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
| | - J S Wang
- Affiliated hospital of Guizhou Medical University, Guiyang 550004, China
| | - H X Yao
- Hainan Provincial People's Hospital, Haikou 570311, China
| | - L G Qiu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J Y Li
- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
| |
Collapse
|
23
|
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol 2023. [PMID: 37128776 DOI: 10.1002/ajh.26943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/12/2023] [Accepted: 04/18/2023] [Indexed: 05/03/2023]
Affiliation(s)
- Sen Yang
- National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Xiaoshuai Zhang
- National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
| | - Robert Peter Gale
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK
| | - Xin Du
- Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China
| | - Chun-Yan Chen
- Department of Haematology, Qilu Hospital, Shandong University, Jinan, China
| | - Jian-Yu Weng
- Department of Haematology, Guangdong Provincial People's Hospital, Guangzhou, China
| | - Jian Huang
- Department of Haematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China
- Department of Haematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Fei Li
- Center of Haematology, The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Yun Zeng
- The First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Zhen Xiao
- The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - Jian-da Hu
- Fujian Medical University Union Hospital, Fuzhou, China
| | - Li-Jie Yang
- Xi'an International Medical Center Hospital, Xi'an, China
| | - Zhuo-Gang Liu
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Guo-Hui Li
- Xi'an International Medical Center Hospital, Xi'an, China
| | - Xiu-Li Sun
- Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Wei Yang
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, Beijing, China
| | - Yan-Qiu Han
- The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - Yu Jing
- Department of Hematology, Chinese People's Liberation Army General Hospital, Beijing, China
| | - Na Xu
- Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Xiao-Li Liu
- Department of Haematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Zhen-Fang Liu
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Xiao-Dong Wang
- Department of Haematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Department of Haematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China
- Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China
| | - Shi-Xin Wu
- The Second Affiliated Hospital of Fujian Medical University, Fujian, China
| | - Rong Liang
- Department of Haematology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
| | - Yan-Li Zhang
- Department of Haematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
| | - Yun-Fan Yang
- Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China
| | - Huan-Ling Zhu
- Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China
| | - Ling Pan
- Department of Haematology, Institute of Haematology, West China Hospital, Sichuan University, Chengdu, China
| | - Li Meng
- Department of Haematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yan-Hong Zhao
- The First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Hai Yi
- Hematology Department, The General Hospital of Western Theater Command, PLA, Chengdu, China
| | - Yi-Lan Liu
- Hematology Department, The General Hospital of Western Theater Command, PLA, Chengdu, China
| | - Wei-Hua Zhang
- First Hospital of Shangxi Medical University, Shangxi, China
| | - Yuan-Jun Zheng
- First Hospital of Shangxi Medical University, Shangxi, China
| | - Ze-Ping Zhou
- Dept. of Hematology, The Second Hospital Affiliated to Kunming medical university, Kunming, China
| | - Su-Ning Chen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China
| | - Hui-Ying Qiu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China
| | - Wei-Ming Li
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zhi-Lin Jia
- Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China
| | - Yan-Liang Bai
- Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China
| | - Li-E Lin
- Hainan General Hospital, Hainan, China
| | - Bing-Cheng Liu
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | | | - Jian-Min Luo
- The Second Hospital of Hebei Medical University, Shijiazhuang, China
| | | | - Zhi-Qiang Sun
- Shenzhen Hospital of Southern Medical University, Shenzhen, China
| | - Yan-Qing Zhang
- Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Xiao-Jun Huang
- National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
- Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
- Research Unit of Key Technique for Diagnosis and Treatments of Haematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China
| | - Qian Jiang
- National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China
- Collaborative Innovation Center of Haematology, Soochow University, Suzhou, China
| |
Collapse
|
24
|
Feng R, Wei H, Xu R, Liu S, Wei J, Guo K, Qiao H, Xu C. Combined Metabolome and Transcriptome Analysis Highlights the Host's Influence on Cistanche deserticola Metabolite Accumulation. Int J Mol Sci 2023; 24:ijms24097968. [PMID: 37175675 PMCID: PMC10178529 DOI: 10.3390/ijms24097968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 04/17/2023] [Accepted: 04/22/2023] [Indexed: 05/15/2023] Open
Abstract
The medicinal plant Cistanche deserticola Ma (Orobanchaceae) is a holoparasitic angiosperm that takes life-essential materials from Haloxylon ammodendron (C. A. Mey.) Bunge (Amaranthaceae) roots. Although many experiments have been conducted to improve the quality of C. deserticola, little attention has been paid to the host's influence on metabolite accumulation. In this study, transcriptomic and metabolomic analyses were performed to unveil the host's role in C. deserticola's metabolite accumulation, especially of phenylethanoid glycosides (PhGs). The results indicate that parasitism by C. deserticola causes significant changes in H. ammodendron roots in relation to metabolites and genes linked to phenylalanine metabolism, tryptophan metabolism and phenylpropanoid biosynthesis pathways, which provide precursors for PhGs. Correlation analysis of genes and metabolites further confirms that C. deserticola's parasitism affects PhG biosynthesis in H. ammodendron roots. Then we found specific upregulation of glycosyltransferases in haustoria which connect the parasites and hosts. It was shown that C. deserticola absorbs PhG precursors from the host and that glycosylation takes place in the haustorium. We mainly discuss how the host resists C. deserticola parasitism and how this medicinal parasite exploits its unfavorable position and takes advantage of host-derived metabolites. Our study highlights that the status of the host plant affects not only the production but also the quality of Cistanches Herba, which provides a practical direction for medicinal plant cultivation.
Collapse
Affiliation(s)
- Ru Feng
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Hongshuang Wei
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Rong Xu
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Sai Liu
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Jianhe Wei
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Kun Guo
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Haili Qiao
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| | - Changqing Xu
- Institute of Medicinal Plant Development, Chinese Academy of Medicinal Science and Peking Union Medicinal College, Beijing 100193, China
| |
Collapse
|
25
|
Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu YX, Riggs AD, Martin PJ, Feng R, Zeng D. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A 2023; 120:e2205085120. [PMID: 37036990 PMCID: PMC10120074 DOI: 10.1073/pnas.2205085120] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2023] Open
Abstract
PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 and CD80/CTLA4 interactions between T and APCs. Here, using tumor-bearing mice capable of cis and trans or trans only PD-L1/CD80 interactions, we show that trans PD-L1/CD80 interactions do exist between tumor and T cells, and the effects of trans PD-L1/CD80 interactions require tumor cell expression of MHC-I and T cell expression of CD28. The blockade of PD-L1/CD80 interactions in mice with both cis and trans interactions or with only trans interactions augments antitumor immunity by expanding IFN-γ-producing CD8+ T cells and IFN-γ-dependent NOS2-expressing tumor-associated macrophages. Our studies indicate that although cis and trans PD-L1/CD80 interactions may have opposite effects on antitumor immunity, the net effect of blocking PD-L1/CD80 interactions in vivo augments CD8+ T cell-mediated antitumor immunity.
Collapse
Affiliation(s)
- Yuankun Zhang
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010
| | - Qingxiao Song
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010
- Fujian Medical University Center of Translational Hematology, Fujian Institute of Hematology, and Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Kaniel Cassady
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Irell & Manella Graduate School of Biological Sciences, City of Hope National Medical Center, Duarte, CA 91010
| | - Michael Lee
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Irell & Manella Graduate School of Biological Sciences, City of Hope National Medical Center, Duarte, CA 91010
| | - Haidong Tang
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390
| | - Moqian Zheng
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010
| | - Bixin Wang
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010
- Fujian Medical University Center of Translational Hematology, Fujian Institute of Hematology, and Fujian Medical University Union Hospital, Fuzhou 350001, China
| | - Dustin E Schones
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
| | - Yang-Xin Fu
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390
| | - Arthur D Riggs
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
| | | | - Ru Feng
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
| | - Defu Zeng
- Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope Medical Center, Duarte, CA 91010
- Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA 91010
| |
Collapse
|
26
|
Peng J, Meng R, Liu X, Zhang L, Wang L, Feng R, Feng H, Huang Z, Yao D, Li X, Liu N, Tan B, Li S, Yu J, Meng X. 172P A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00426-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
27
|
Feng R, Yin H, Jin F, Niu W, Zhang W, Liu J, Du A, Yang W, Liu Z. Highly Selective N2 Electroreduction to NH3 Using a Boron-Vacancy-Rich Diatomic NbB Catalyst. Small 2023:e2301627. [PMID: 36974604 DOI: 10.1002/smll.202301627] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Indexed: 06/18/2023]
Abstract
The ambient electrochemical N2 reduction reaction (NRR) is a future approach for the artificial NH3 synthesis to overcome the problems of high-energy consumption and environmental pollution by Haber-Bosch technology. However, the challenge of N2 activation on a catalyst surface and the competitive hydrogen evolution reaction make the current NRR unsatisfied. Herein, this work demonstrates that NbB2 nanoflakes (NFs) exhibit excellent selectivity and durability in NRR, which produces NH3 with a production rate of 30.5 µg h-1 mgcat -1 and a super-high Faraday efficiency (FE) of 40.2%. The high-selective NH3 production is attributed to the large amount of active B vacancies on the surface of NbB2 NFs. Density functional theory calculations suggest that the multiple atomic adsorption of N2 on both unsaturated Nb and B atoms results in a significantly stretched N2 molecule. The weakened NN triple bonds are easier to be broken for a biased NH3 production. The diatomic catalysis is a future approach for NRR as it shows a special N2 adsorption mode that can be well engineered.
Collapse
Affiliation(s)
- Ru Feng
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| | - Hanqing Yin
- School of Chemistry and Physics and Centre for Materials Science, Queensland University of Technology, Gardens Point Campus, Brisbane, 4001, Australia
| | - Fuhao Jin
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| | - Wei Niu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| | - Wanting Zhang
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| | - Jingquan Liu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| | - Aijun Du
- School of Chemistry and Physics and Centre for Materials Science, Queensland University of Technology, Gardens Point Campus, Brisbane, 4001, Australia
| | - Wenrong Yang
- School of Life and Environmental Sciences, Deakin University, 75 Pigdons Road, Geelong, VIC 3216, Australia
| | - Zhen Liu
- College of Materials Science and Engineering, Institute for Graphene Applied Technology Innovation, Qingdao University, 308 Ningxia Road, Qingdao, 266071, P. R. China
| |
Collapse
|
28
|
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Validation of the imatinib-therapy failure model. Leukemia 2023; 37:1166-1169. [PMID: 36973351 DOI: 10.1038/s41375-023-01875-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/01/2023] [Accepted: 03/10/2023] [Indexed: 03/29/2023]
Affiliation(s)
- Xiaoshuai Zhang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
| | - Robert Peter Gale
- Centre for Hematology Research, Department of Immunology and Inflammation, Imperial College London, London, UK
| | - Bingcheng Liu
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
| | - Jian Huang
- Department of Hematology, he First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University, Zhejiang Provincial Clinical Research Center for Haematological Disorders, Zhejiang, China
| | - Yanli Zhang
- Henan Cancer Hospital, The Affiliate Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Xin Du
- Division of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Guangdong, China
| | - Jianyu Weng
- Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Weiming Li
- Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China
| | - Na Xu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Xiaoli Liu
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Chunyan Chen
- Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
| | - Hai Lin
- Department of hematology, First Hospital of Jilin University, Jilin, China
| | - Guohui Li
- Xi'an international medical center hospital, Shanxi, China
| | - Rong Liang
- Department of Hematology, Xijing Hospital, Airforce Military Medical University, Shanxi, China
| | - Zhuogang Liu
- Shengjing Hospital of China Medical University, Shenyang, China
| | - Xiaodong Wang
- Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
| | - Yanqing Zhang
- Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
| | - Yanqiu Han
- The affiliated hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - Chunshui Liu
- Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China
| | - Jianda Hu
- Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fujian, China
| | - Lie Lin
- Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
| | - Wei Yang
- Shengjing Hospital of China Medical University, Shenyang, China
| | - Zhenfang Liu
- Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Li Meng
- Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Chuanqing Tu
- Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China
| | - Caifeng Zheng
- Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China
| | - Zeping Zhou
- Department of Hematology, the Second Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China
| | - Yanliang Bai
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China
| | - Huiying Qiu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China
| | - Suning Chen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Suzhou, China
| | - Fei Li
- Center of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China
| | - Jianxin Guo
- Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China
| | - Zelin Liu
- Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China
| | - Hui Sun
- Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Li Zhou
- Department of Leukemia, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Beijing, China
| | - Xiuli Sun
- Department of hematology, The first affiliated hospital of Dalian Medical University, Dalian, China
| | - Xiaojun Huang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
- Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
- Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 1, China.
- Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.
| | - Qian Jiang
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
- Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
| |
Collapse
|
29
|
Wang GC, Li HL, Liu Y, Gu XH, Liu RX, Feng R, Wang YC, Liu YJ, Zhang GQ, Zhang Z, Wang HL, Wang F, Zhang Y. [Analysis of the causes of long-standing pelvic anterior sacral space infection and discussion of management techniques]. Zhonghua Zhong Liu Za Zhi 2023; 45:273-278. [PMID: 36944549 DOI: 10.3760/cma.j.cn112152-20210217-00136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/23/2023]
Abstract
Objective: To investigate the causes and management of long-term persistent pelvic presacral space infection. Methods: Clinical data of 10 patients with persistent presacral infection admitted to the Cancer Hospital of Zhengzhou University from October 2015 to October 2020 were collected. Different surgical approaches were used to treat the presacral infection according to the patients' initial surgical procedures. Results: Among the 10 patients, there were 2 cases of presacral recurrent infection due to rectal leak after radiotherapy for cervical cancer, 3 cases of presacral recurrent infection due to rectal leak after radiotherapy for rectal cancer Dixons, and 5 cases of presacral recurrent infection of sinus tract after adjuvant radiotherapy for rectal cancer Miles. Of the 5 patients with leaky bowel, 4 had complete resection of the ruptured nonfunctional bowel and complete debridement of the presacral infection using an anterior transverse sacral incision with a large tipped omentum filling the presacral space; 1 had continuous drainage of the anal canal and complete debridement of the presacral infection using an anterior transverse sacral incision. 5 post-Miles patients all had debridement of the presacral infection using an anterior transverse sacral incision combined with an abdominal incision. The nine patients with healed presacral infection recovered from surgery in 26 to 210 days, with a median time of 55 days. Conclusions: Anterior sacral infections in patients with leaky gut are caused by residual bowel secretion of intestinal fluid into the anterior sacral space, and in post-Miles patients by residual anterior sacral foreign bodies. An anterior sacral caudal transverse arc incision combined with an abdominal incision is an effective surgical approach for complete debridement of anterior sacral recalcitrant infections.
Collapse
Affiliation(s)
- G C Wang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China Department of Gneneral Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050004, China
| | - H L Li
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - Y Liu
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - X H Gu
- Henan Institute of Medical Information, Zhengzhou 450018, China
| | - R X Liu
- Henan Institute of Medical Information, Zhengzhou 450018, China
| | - R Feng
- Henan Institute of Medical Information, Zhengzhou 450018, China
| | - Y C Wang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - Y J Liu
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - G Q Zhang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - Z Zhang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - H L Wang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - F Wang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| | - Y Zhang
- Department of General Surgery, Affiliated Cancer Hospital of Zhengzhou University, He'nan Provincial Cancer Hospital, Zhengzhou 450003, China
| |
Collapse
|
30
|
Li J, Han LH, Feng R, Wu LH, Cai J, Zeng TY, Liu H, Zeng YW, Zhou L, Zhan ZQ. Validation of the JAMR F1701T (arm type) pressure monitor according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/ISO 81060-2:2018 protocol. Blood Press Monit 2023; 28:163-166. [PMID: 37016972 PMCID: PMC10132453 DOI: 10.1097/mbp.0000000000000643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/06/2023]
Abstract
To validate the JAMR F1701T (arm type) blood pressure (BP) monitor according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Universal Standard (ISO 81060-2:2018). A total of 90 subjects (male 60 and female 30) were recruited to fulfill the criteria of the AAMI/ESH/ISO Universal Standard (the number, gender, age, limber size, and BP distribution), and sequential measurements of BP, including both SBP and DBP were obtained using the test device and the standard mercury sphygmomanometer. A total of 270 sets of comparison data (three sets of each subject) were obtained and analyzed. According to the validation criterion 1 of ISO 81060-2:2018, the mean ± SD of the differences between the JAMR F1701T and mercury sphygmomanometer BP (systolic/diastolic) readings was 2.06 ± 6.83/-4.84 ± 5.23 mmHg. For criterion 2, the SD of the averaged BP (systolic/diastolic) differences between the JAMR F1701 and reference BP (systolic/diastolic) per participant was 5.62/4.39 mmHg (the requirement was ≤6.43/5.01 mmHg by calculation). The JAMR F1701T met all the requirements of the ISO 81060-2:2018, and can be recommended for clinical and self/home use.
Collapse
Affiliation(s)
- Jing Li
- Department of Cardiology, Shenzhen Hospital, University of Chinese Academy of Sciences, Guangming District, Shenzhen, Guangdong Province, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Xu W, Yang S, Zhou K, Pan L, Li Z, Gao S, Zhou D, Hu J, Feng R, Huang H, Wang T, Li D, Ji M, Guo H, Zhao X, Wu B, Yu Y, Wang Y, Huang J, Novotny W, Li J. Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. Leuk Lymphoma 2023; 64:712-716. [PMID: 36799536 DOI: 10.1080/10428194.2022.2164692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Affiliation(s)
- Wei Xu
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, China
| | - Shenmiao Yang
- Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China
| | - Keshu Zhou
- Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
| | - Ling Pan
- West China Hospital of Sichuan University, Chengdu, China
| | - Zengjun Li
- Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China
| | - Sujun Gao
- The First Hospital of Jilin University, Changchun, China
| | - Daobin Zhou
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Jianda Hu
- Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
| | - Ru Feng
- Nanfang Hospital of Southern Medical University, Guangzhou, China
| | - Haiwen Huang
- The First Hospital of Soochow University, Suzhou, China
| | - Tingyu Wang
- Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China
| | - Dengju Li
- Tongji Hospital, Tongji Medical College, Wuhan, China
| | - Meng Ji
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Haiyi Guo
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Xia Zhao
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Binghao Wu
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Yiling Yu
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Yu Wang
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Jane Huang
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - William Novotny
- BeiGene (Beijing) Co., Ltd., Beijing, China
- BeiGene (Shanghai) Co., Ltd., Shanghai, China
- BeiGene USA, Inc., San Mateo, CA, USA
| | - Jianyong Li
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing, China
| |
Collapse
|
32
|
Zhang S, Feng R, Bai J, Ning S, Xu X, Sun J, Wu M, Liu H. CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo. Leuk Lymphoma 2023; 64:639-650. [PMID: 36657437 DOI: 10.1080/10428194.2023.2169045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
THZ1, a CDK7 inhibitor, has potent antitumor effects in several cancers; however, its role in Acute myeloid leukemia (AML) is unclear. We explored the effects and potential mechanisms of THZ1, alone and in combination with azacitidine (AZA), in AML cells and xenograft models. THZ1 decreased cell viability, induced apoptosis in a dose and time-dependent manner, induced G0/G1 cell cycle arrest, decreased phosphorylated CDK1 and CDK2 expression, and inhibited RNA Pol II phosphorylation at multiple serine sites. The combination of AZA and THZ1 exhibited synergistic antileukemic effects in AML cell lines and primary cells with MCL1 and c-MYC downregulation. Moreover, the combination therapy significantly decreased tumor burden and prolonged animal survival in xenograft mice models. Our data demonstrate that CDK7 inhibition induces the apoptosis of AML cells and exerts a synergistic antileukemia effect with AZA in vitro and in vivo, which supports future exploration of this combination in clinical studies.
Collapse
Affiliation(s)
- Shuai Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Jiefei Bai
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Shangyong Ning
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Xiaodong Xu
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Jie Sun
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Meng Wu
- Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
33
|
Liu W, Zhang J, Kang Q, Chen H, Feng R. Enhanced photocatalytic degradation performance of In 2O 3/g-C 3N 4 composites by coupling with H 2O 2. Ecotoxicol Environ Saf 2023; 252:114611. [PMID: 36753972 DOI: 10.1016/j.ecoenv.2023.114611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Revised: 01/31/2023] [Accepted: 02/01/2023] [Indexed: 06/18/2023]
Abstract
Environmental pollution by organic pollutants poses a great threat to the ecosystem and human development. Solar-powered catalytic oxidation technology can solve the existing energy and pollution crisis. Hence, in this work, cubic nano-In2O3 modified g-C3N4 composite was synthesized by in situ calcination, then it was coupled with hydrogen peroxide for the degradation of antibiotic under visible light. The results of SEM and XPS showed that In2O3 and g-C3N4 were closely combined. The catalytic oxidation efficiency of the antibiotic doxycycline was greatly improved when the as-prepared compound was coupled with hydrogen peroxide, and 88.2% of doxycycline was degraded within 80 min. By designing the active species inhibition test, it was found that a large number of hydroxyl radicals were generated in the system after adding hydrogen peroxide, which accelerated the degradation of the target. Hydrogen peroxide not only acts as a source of hydroxyl radical, but also as an active electron acceptor, which promotes the separation of photogenerated electron-hole pairs in the composite photocatalyst. Therefore, the double oxidation system formed by In2O3/g-C3N4 coupled with hydrogen peroxide can degrade the target at a higher rate. This work provided a research basis for the synthesis of In2O3 with regular morphology and simplified synthesis of In2O3/g-C3N4, and explored the practicability of the coupling method of double advanced oxidation for pollutant degradation.
Collapse
Affiliation(s)
- Wei Liu
- Faculty of Resources and Environmental Science, Hubei University, Wuhan 430062, China; School of Mechatronic Engineering, Wuhan Business University, Wuhan 430056, China
| | - Jin Zhang
- Faculty of Resources and Environmental Science, Hubei University, Wuhan 430062, China.
| | - Qun Kang
- Faculty of Resources and Environmental Science, Hubei University, Wuhan 430062, China
| | - Hongbing Chen
- Faculty of Resources and Environmental Science, Hubei University, Wuhan 430062, China
| | - Ru Feng
- Faculty of Resources and Environmental Science, Hubei University, Wuhan 430062, China
| |
Collapse
|
34
|
Lyu L, Li X, Feng R, Zhou X, Guha TK, Yu X, Chen GQ, Yao Y, Su B, Zou D, Snyder MP, Chen L. Simultaneous profiling of host expression and microbial abundance by spatial metatranscriptome sequencing. Genome Res 2023; 33:401-411. [PMID: 37310927 PMCID: PMC10078289 DOI: 10.1101/gr.277178.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 01/31/2023] [Indexed: 03/29/2023]
Abstract
We developed an analysis pipeline that can extract microbial sequences from spatial transcriptomic (ST) data and assign taxonomic labels, generating a spatial microbial abundance matrix in addition to the default host expression matrix, enabling simultaneous analysis of host expression and microbial distribution. We called the pipeline spatial metatranscriptome (SMT) and applied it on both human and murine intestinal sections and validated the spatial microbial abundance information with alternative assays. Biological insights were gained from these novel data that showed host-microbe interaction at various spatial scales. Finally, we tested experimental modification that can increase microbial capture while preserving host spatial expression quality and, by use of positive controls, quantitatively showed the capture efficiency and recall of our methods. This proof-of-concept work shows the feasibility of SMT analysis and paves the way for further experimental optimization and application.
Collapse
Affiliation(s)
- Lin Lyu
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Xue Li
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Ru Feng
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Xin Zhou
- Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
| | - Tuhin K Guha
- Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA
| | - Xiaofei Yu
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Shanghai Engineering Research Center of Industrial Microorganisms, Fudan University, Shanghai 20082, China
| | - Guo Qiang Chen
- Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, State Key Laboratory of Oncogenes and Related Genes and Chinese Academy of Medical Sciences, Shanghai Cancer Institute, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Yufeng Yao
- Laboratory of Bacterial Pathogenesis, Department of Microbiology and Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Bing Su
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Duowu Zou
- Department of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
| | - Michael P Snyder
- Department of Genetics, Stanford University School of Medicine, Stanford, California 94305, USA;
| | - Lei Chen
- Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
- Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
| |
Collapse
|
35
|
He D, Pan C, Zhao Y, Wei W, Qin X, Cai Q, Shi S, Chu X, Zhang N, Jia Y, Wen Y, Cheng B, Liu H, Feng R, Zhang F, Xu P. Exome-wide screening identifies novel rare risk variants for bone mineral density. Osteoporos Int 2023; 34:965-975. [PMID: 36849660 DOI: 10.1007/s00198-023-06710-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Accepted: 02/14/2023] [Indexed: 03/01/2023]
Abstract
UNLABELLED Bone mineral density (BMD) is an independent risk factor of osteoporosis-related fractures. We performed gene-based burden tests to assess the association between rare variants and BMD, and identified several BMD candidate genes. PURPOSE BMD is highly heritable and a major predictor of osteoporotic fractures, but its genetic basis remains unclear. We aimed to identify rare risk variants contributing to BMD. METHODS Utilizing the newly released UK Biobank 200,643 exome dataset, we conducted a gene-based exome-wide association study in males and females, respectively. First, 100,639 males and 117,338 females with BMD values were included in the polygenic risk scores (PRS) analysis. Among individuals with lower 30% PRS, cases were individuals with top 10% BMD, and individuals with bottom 10% BMD were the controls. Considering the effects of vitamin D (VD), individuals with the highest 30% VD concentration were selected for VD-BMD analysis. After quality control, 741 males and 697 females were included in the BMD analysis, and 717 males and 708 females were included in the VD-BMD analysis. The variants were annotated by ANNOVAR software, then BMD and VD-BMD qualified variants were imported into the SKAT R-package to perform gene-based burden tests, respectively. RESULTS The gene-based burden test of the exonic variants identified genome-wide candidate associations in ANKRD18A (P = 1.60 × 10-5, PBonferroni adjust = 2.11 × 10-3), C22orf31 (P = 3.49 × 10-4, PBonferroni adjust = 3.17 × 10-2), and SPATC1L (P = 1.09 × 10-5, PBonferroni adjust = 8.80 × 10-3). For VD-BMD analysis, three genes were associated with BMD, such as NIPAL1 (P = 1.06 × 10-3, PBonferroni adjust = 3.91 × 10-2). CONCLUSIONS Our study suggested that rare variants contribute to BMD, providing new sights for broadening the genetic structure of BMD.
Collapse
Affiliation(s)
- D He
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - C Pan
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - Y Zhao
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - W Wei
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - X Qin
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - Q Cai
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - S Shi
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - X Chu
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - N Zhang
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - Y Jia
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - Y Wen
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - B Cheng
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - H Liu
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China
| | - R Feng
- Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China
| | - F Zhang
- Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission, Xi'an Jiaotong University, Xi'an, China.
- Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China, Xi'an Jiaotong University, Xi'an, China.
- Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, Xi'an Jiaotong University, Xi'an, China.
- School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.
| | - P Xu
- Department of Joint Surgery, HongHui Hospital, Xi'an Jiaotong University, Xi'an, China.
| |
Collapse
|
36
|
Zhang S, Feng R, Bai J, Ning S, Xu X, Sun J, Wu M, Liu H. CDK7 inhibition induces apoptosis in acute myeloid leukemia cells and exerts synergistic antileukemic effects with azacitidine in vitro and in vivo. Leuk Lymphoma 2023; 64:639-650. [DOI: doi:10.1080/10428194.2023.2169045 i] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 12/25/2022] [Accepted: 01/02/2023] [Indexed: 12/05/2023]
Affiliation(s)
- Shuai Zhang
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Jiefei Bai
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Shangyong Ning
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Xiaodong Xu
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Jie Sun
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
| | - Meng Wu
- Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China
- Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
37
|
Yu H, Wen B, Huang M, Feng R, Pan L, Xu M, Lin H, Cong L, Zhang S, Li Y, Cho CH, Zhang C, Chen X, Wang Y. TCP-1, a novel peptide to diagnose early colon cancer. CHINESE CHEM LETT 2023. [DOI: 10.1016/j.cclet.2023.108235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
38
|
Zhong Q, Zhan J, Yang H, Zhu N, Feng R, Yao Y. A New Method of Nice Knot Elastic Fixation for Distal Tibiofibular Syndesmosis Injury. Orthop Surg 2023; 15:785-792. [PMID: 36710316 PMCID: PMC9977588 DOI: 10.1111/os.13635] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/22/2022] [Accepted: 11/24/2022] [Indexed: 01/31/2023] Open
Abstract
OBJECTIVE The distal tibiofibular syndesmosis (DTS) is a fretting joint and it is still a hot issue how to satisfy strong internal fixation while allowing fretting. This study described and evaluated a new method for elastic fixation of DTS injury with Nice Knot. METHODS The study was designed as a retrospective study. Between June 2020 and June 2021, 31 patients who were diagnosed with ankle fracture and DTS injury without additional orthopedic injuries were enrolled in this case series. The study included 22 males and nine females, with an average age of 34.71 ± 14.66 years. All patients were treated with Nice Knot binding for DTS. Surgical time, length of stay, time of DTS fixation, total weight-bearing time, complications, imaging parameters, and functional scores at follow-up were recorded. Paired sample t-tests or single factor analyses of variance were used at intra-group comparison. RESULTS All patients completed surgery with normal syndesmotic parameters. The recovery of DTS injury was verified by Hook and lateral malleolus rotation tests. The average follow-up time was 15.97 ± 3.30 months. Only one case showed superficial infection after surgery, and the wound healed after symptomatic treatment. In terms of imaging, there were no significant differences in tibiofibular clear space (TFCS), tibiofibular overlap distance (TFOS), medial clear space (MCS), and superior clear space (SCS) immediately and at different follow-up points after surgery. All obtained excellent and good outcomes according to the AOFAS score at least follow-up after surgery. CONCLUSIONS Nice Knot elastic fixation of DTS injury is firm and stable while maintaining the physiological micromotion of the ankle joint.
Collapse
Affiliation(s)
- Qigang Zhong
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| | - Junfeng Zhan
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| | - Hu Yang
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| | - Nan Zhu
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| | - Ru Feng
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| | - Yunfeng Yao
- Second Affiliated Hospital of Anhui Medical UniversityHefeiChina
| |
Collapse
|
39
|
Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW, Yu H, Dong F, Liao A, Ma Y, Liu Q, Liu S, Jing H, Fu R, Ma LM, Liu H, Sun W, Bao L, Wu Y, Chen W, Zhuang J. Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China. Front Oncol 2023; 13:1028571. [PMID: 37152063 PMCID: PMC10157094 DOI: 10.3389/fonc.2023.1028571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 03/29/2023] [Indexed: 05/09/2023] Open
Abstract
Maintenance treatment is a pivotal part in the whole process management of multiple myeloma (MM), which further deepens response and improves survival. However, evidence of maintenance in non-transplant MM patients is inadequate in real-world practice. Here, we retrospectively analyzed the efficacy and survival of 375 non-transplant MM patients from 11 centers between 2010 and 2021 in north China. After a median of seven cycles of front-line regimens, there were 141, 79, and 155 patients receiving lenalidomide maintenance (L-MT), bortezomib maintenance (B-MT), or thalidomide maintenance (T-MT), respectively. Patients on L-MT and B-MT had significantly greater proportions of high-risk cytogenetic abnormalities (HRCAs) detected by fluorescence in situ hybridization (FISH), which was defined as 1q21 gain, 17p deletion, adverse immunoglobulin heavy chain (IgH) translocations. Although the progression-free survival (PFS) and overall survival (OS) were comparable among the three groups, L-MT and B-MT remedied the negative impact of HRCAs on survival (PFS of patients with HRCAs vs. patients without HRCAs: L-MT, 26.9 vs. 39.2 months, p=0.19; B-MT, 20.0 vs. 29.7 months, p=0.36; OS not reached in all groups). Patients with HRCAs in the T-MT group presented inferior clinical outcomes compared to standard-risk patients (PFS, 12.1 vs. 22.8 months, p=0.02, HR=1.8, 95% CI 1.0-3.4; OS, 54.9 months vs. NR, p<0.001, HR=3.2, 95% CI 1.5-7.0). Achieving complete response (CR) after induction therapy led to superior PFS compared to other degrees of response, regardless of maintenance medication. Furthermore, maintenance duration over 24 months correlated with favorable survival. Due to the large gap of transplant eligibility in China, optimizing maintenance therapy is important for non-transplant MM patients. In this real-world multi-centered study, our findings suggest that clinicians prefer to prescribe lenalidomide or bortezomib as maintenance therapy in high-risk settings, which are superior to thalidomide in non-transplant MM patients. Achievement of CR and maintenance duration over 2 years are positive factors that influence survival.
Collapse
Affiliation(s)
- Zhe Zhuang
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - Ying Tian
- Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China
| | - Lei Shi
- Department of Hematology, Beijing University, Beijing Jishuitan Hospital, Beijing, China
| | - Dongmei Zou
- Department of Hematology, Xuanwu Hospital Capital Medical University, Beijing, China
| | - Ru Feng
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China
| | - Wei-wei Tian
- Department of Hematology, Shanxi Bethune Hospital of Shanxi Medical University, Taiyuan, China
| | - Hong Yu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Fei Dong
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Aijun Liao
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Yanping Ma
- Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China
| | - Qinhua Liu
- Department of Hematology, First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Shuangjiao Liu
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Rong Fu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
| | - Liang-ming Ma
- Department of Hematology, Shanxi Bethune Hospital of Shanxi Medical University, Taiyuan, China
| | - Hui Liu
- Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China
| | - Wanling Sun
- Department of Hematology, Xuanwu Hospital Capital Medical University, Beijing, China
| | - Li Bao
- Department of Hematology, Beijing University, Beijing Jishuitan Hospital, Beijing, China
- *Correspondence: Li Bao, ; Yin Wu, ; Wenming Chen, ; Junling Zhuang,
| | - Yin Wu
- Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China
- *Correspondence: Li Bao, ; Yin Wu, ; Wenming Chen, ; Junling Zhuang,
| | - Wenming Chen
- Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China
- *Correspondence: Li Bao, ; Yin Wu, ; Wenming Chen, ; Junling Zhuang,
| | - Junling Zhuang
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
- *Correspondence: Li Bao, ; Yin Wu, ; Wenming Chen, ; Junling Zhuang,
| |
Collapse
|
40
|
Su F, Zhu M, Feng R, Li Y. ME-NBI combined with endoscopic ultrasonography for diagnosing and staging the invasion depth of early esophageal cancer: a diagnostic meta-analysis. World J Surg Oncol 2022; 20:343. [PMID: 36253783 PMCID: PMC9575268 DOI: 10.1186/s12957-022-02809-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 10/02/2022] [Indexed: 12/24/2022] Open
Abstract
Background Several methods can assist in detecting early esophageal cancer (EEC) and staging esophageal cancer (EC) invasion depth. Objective To evaluate the accuracy of magnifying endoscopy with narrow-band imaging (ME-NBI) plus endoscopic ultrasonography (EUS) for diagnosing EC. Methods We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases for relevant studies. The Quality Assessment of Diagnostic Accuracy Studies 2 (QADAS2) was used to assess the studies’ methodological quality. The sensitivity, specificity, positive likelihood (LR+), negative likelihood (LR−), and diagnostic odds ratio (DOR) were calculated, and the summary receiver operating characteristic (SROC) curves were drawn to evaluate the diagnostic performance. Results Seven studies were included. The meta-analysis suggested that the pooled sensitivity, specificity, LR+, LR−, and DOR of ME-NBI plus EUS for diagnosing EC were 0.947 (95% confidence interval [CI], 0.901–0.975), 0.894 (95% CI, 0.847–0.931), 7.989 (95% CI, 4.264–14.970), 0.066 (95% CI, 0.035–0.124), and 137.96 (95% CI, 60.369–315.27), respectively. Those values for staging the invasive depth were 0.791 (95% CI, 0.674–0.881), 0.943 (95% CI, 0.906–0.968), 13.087 (95% CI, 7.559–22.657), 0.226 (95% CI, 0.142–0.360), and 61.332 (95% CI, 27.343–137.57). The areas under the curves (AUCs) for diagnosis and staging were 0.97 and 0.95, respectively. Conclusions ME-NBI plus EUS might be an adequate diagnostic and staging modality for EC. Due to the study limitations, more large-scale, high-quality studies are needed to confirm the diagnostic accuracy of ME-NBI plus EUS. Supplementary Information The online version contains supplementary material available at 10.1186/s12957-022-02809-6.
Collapse
Affiliation(s)
- Feng Su
- Department of Gastroenterology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu Province, 223800, China
| | - Meiling Zhu
- Department of Gastroenterology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu Province, 223800, China
| | - Ru Feng
- Department of Gastroenterology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu Province, 223800, China
| | - Yunhong Li
- Department of Gastroenterology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian Hospital of Nanjing Drum Tower Hospital Group, Suqian, Jiangsu Province, 223800, China.
| |
Collapse
|
41
|
Ruiperez-Campillo S, Deb B, Feng R, Ganesan P, Tjong FVY, Clopton P, Rogers AJ, Narayan SM. Reduction of artifacts and noise in small electrogram datasets without manual annotation using transfer machine learning. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background/Introduction
Mapping AF is challenging. Monophasic action potentials (MAPs) show that most of the recorded signals are not representing the atrial activity, and arise from far-field or other artifacts. Thus, reducing noise in electrophysiological signals is essential, yet it can be difficult for cross-talk from other chambers and pacing. Strategies to reduce noise include template matching, averaging, and smoothing, but all of them have major limitations. Furthermore, expert interpretation requires knowledge to discriminate signals from noise, but is subjective.
Purpose
We hypothesised a) that atrial and ventricular electrograms with varying artifact and noise can be denoised using autoencoder neural networks (NNs) without requiring manual annotation and in a reproducible manner, and b) we could train these NNs on a large available dataset ventricular signals, then apply transfer learning to the original smaller atrial dataset. We applied this approach to MAPs, which have interpretable shapes and would help identifying local from far-field signals helping in diagnosis, mapping and ablation.
Methods
We first trained with 5706 left and right ventricular MAPs from 42 patients with ischemic cardiomyopathy (age 65±13y; Fig. 1A), with 60% for training, 20% (validation) and 20% (testing). Transfer learning and parameter-tuning were then used to apply this NN to a smaller sample of atrial MAPs (N=641 from 21 patients, 67±5y, 13 women; Fig. 2B, D, F). The autoencoder was used to eliminate pacing artifacts in ventricular MAPs (Fig. 1B, C) and denoise atrial MAPs (Fig. 2C, E, G) by reconstructing key learned features. The accuracy of the reconstruction was evaluated using Pearson Correlation Coefficient (PCC) and a novel similarity coefficient (SC). No manual annotation was required to identify noisy signals.
Results
The trained NN encoder learned key features of ventricular MAPs and reconstructed these clean signals with a SC=0.91±0.16 and PCC=0.99±0.01 (Fig. 1A). With this training, the NN was able to denoise ventricular MAPs with pacing artifact (Fig. 1B, C). After fine-tuning, the NN learned key signal features (upstroke, triangular descent, terminus) and thus reduced diverse noise without specific training or manual annotation. Namely, it was able to reconstruct atrial MAPs eliminating ventricular noise, high frequency noise and truncated signals (Fig. 2).
Conclusions
Machine learned encoder-decoders are powerful tools that can learn essential features of atrial and ventricular signals and hence isolate noise. Transfer learning is effective when large datasets are unavailable for training. This approach can separate atrial beats from far-field ventricular beats and other sources of noise. The ability to eliminate a diverse range of noise improves this approach over existing techniques and may have far-reaching applications in electrophysiology, such as mapping and ablation.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NIH
Collapse
Affiliation(s)
- S Ruiperez-Campillo
- Stanford University School of Medicine , Palo Alto , United States of America
| | - B Deb
- Stanford University School of Medicine , Palo Alto , United States of America
| | - R Feng
- Stanford University School of Medicine , Palo Alto , United States of America
| | - P Ganesan
- Stanford University School of Medicine , Palo Alto , United States of America
| | - F V Y Tjong
- Stanford University School of Medicine , Palo Alto , United States of America
| | - P Clopton
- Stanford University School of Medicine , Palo Alto , United States of America
| | - A J Rogers
- Stanford University School of Medicine , Palo Alto , United States of America
| | - S M Narayan
- Stanford University School of Medicine , Palo Alto , United States of America
| |
Collapse
|
42
|
Ganesan P, Rogers AJ, Deb B, Feng R, Ruiperez-Campillo S, Tjong FV, Bhatia N, Clopton P, Rappel WJ, Narayan SM. Novel electrogram featurization reveals a spectrum of response to ablation from atrial tachycardia to types of atrial fibrillation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Although atrial tachycardia (AT) may interconvert with fibrillation (AF) in many patients, it is undefined if this represents a pathophysiological spectrum of organization, or whether it indicates that AF will respond better to ablation.
Objective
To test the hypothesis that the spatial area within which electrograms (EGMs) repeat in synchronized fashion over time indicates a spectrum from AT, in which areas span the entire atria, to AF, in which areas are limited. We further hypothesized that repetitive areas would be larger in AF patients with acute termination than in those with poor response to ablation.
Methods
We studied N=234 patients (47% women, 64±10Y), of whom (i) N=10 had AT, (ii) N=120 had AF that terminated with ablation (“Term”), (ii) N=104 had AF that did not terminate (“Non-term”). All patients had global left atrial mapping by 64 pole baskets (Abbott, IL). Spatial areas of repetitive activity (REACT) were calculated by correlating unipolar EGMs in 2x2 grids for 4 sec, repeated for the entire atria (Figure 1A, B). We quantified global organization by averaging the REACT map for each patient.
Results
Figure 1C shows progressively decreasing areas of repetitive EGM from AT to AF Term to AF Non-term (p<0.001, ANOVA). Figure 1D shows a case of AT in a 71 YO male and global REACT >0.90, a case of AF REACT 0.45 in a 65 YO male with termination by ablation, and a case of AF with REACT 0.19 in an 85 YO male that did not terminate. Further, ROC analysis of REACT analysis in AF cases predicted termination with an AUC of 0.71.
Conclusion
Spatial areas of repeating electrogram shapes indicates a spectrum from AT to AF with good and AF with poor acute response to ablation. Future studies should investigate whether REACT areas can be identified non-invasively, such as by body surface ECG, to guide ablation or prognosis.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): US National Institutes of Health
Collapse
Affiliation(s)
- P Ganesan
- Stanford University School of Medicine , Palo Alto , United States of America
| | - A J Rogers
- Stanford University School of Medicine , Palo Alto , United States of America
| | - B Deb
- Stanford University School of Medicine , Palo Alto , United States of America
| | - R Feng
- Stanford University School of Medicine , Palo Alto , United States of America
| | | | - F V Tjong
- Stanford University School of Medicine , Palo Alto , United States of America
| | - N Bhatia
- Emory University , Atlanta , United States of America
| | - P Clopton
- Stanford University School of Medicine , Palo Alto , United States of America
| | - W J Rappel
- University of California San Diego , San Diego , United States of America
| | - S M Narayan
- Stanford University School of Medicine , Palo Alto , United States of America
| |
Collapse
|
43
|
Ganesan P, Rogers AJ, Deb B, Feng R, Rodrigo M, Ruiperez-Campillo S, Tjong FV, Bhatia N, Clopton P, Rappel WJ, Narayan SM. Spatiotemporal signatures of response to atrial fibrillation ablation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Atrial fibrillation (AF) can have organized regions, in the form of consistent dominant frequency sites, focal or reentrant sites, but it is unclear how these overlap with or differ from focal atrial tachycardias (AT) or potential drivers. We set out to develop an intuitive method based on fundamental electrogram shape and timing to separate types of AF.
Objective
To test the hypothesis that spatial regions of electrogram (EGM) in AF that show similar shapes over time based on cross-correlation analysis may separate patients with differing response to ablation.
Methods
We recruited N=133 patients (63.8±12.1 Y, 32% women), (i) N=10 had AT, (ii) N=122 AF that was or was not terminated by ablation, and (iii) N=1 pacing. All patients had left atrial mapping by 64 pole baskets. We applied repetitive activity (REACT) mapping that correlates EGMs in contiguous 2x2 regions (Fig. 1A) over 4sec. To calibrate REACT, we introduced simulated variations in shape (gaussian noise) and timing (gaussian delay) to pacing EGMs and computed nomograph over 100 random trials (Fig. 1C).
Results
Fig. 1B shows that REACT in a 71-year-old man with AT is more organized than in a 65 YO man with AF (100% vs 40% mapped field). Overall, REACT was higher in AT than AF (0.63±0.15 vs 0.36±0.22, p<0.001). There were 24 cases in which global REACT between AF and AT groups had the overlapping range of values, indicating organized “islands” in AF analogous to AT. From nomograph in Fig. 1C we identified that this overlap reflects 15 ms variation in cycle length and 20% variation in EGM shape (labelled “x” in Fig. 1C).
Conclusion
Basic electrogram properties in AF of similar shapes in spatial areas over time can separate response to ablation and may represent “islands” of AT. Future studies should investigate the mechanisms for such islands and whether they may be targeted for therapy.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): US National Institutes of Health
Collapse
Affiliation(s)
- P Ganesan
- Stanford University School of Medicine , Palo Alto , United States of America
| | - A J Rogers
- Stanford University School of Medicine , Palo Alto , United States of America
| | - B Deb
- Stanford University School of Medicine , Palo Alto , United States of America
| | - R Feng
- Stanford University School of Medicine , Palo Alto , United States of America
| | - M Rodrigo
- University of Valencia , Valencia , Spain
| | | | - F V Tjong
- Stanford University School of Medicine , Palo Alto , United States of America
| | - N Bhatia
- Emory University , Atlanta , United States of America
| | - P Clopton
- Stanford University School of Medicine , Palo Alto , United States of America
| | - W J Rappel
- University of California San Diego , San Diego , United States of America
| | - S M Narayan
- Stanford University School of Medicine , Palo Alto , United States of America
| |
Collapse
|
44
|
Feng R, Deb B, Ganesan P, Rogers AJ, Ruiperez-Campillo S, Clopton P, Tjong FV, Chang HJ, Rodrigo M, Zaharia M, Narayan SM. Automatic left atrial segmentation from cardiac CT using computer graphics imaging and deep learning. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Segmenting left atrial (LA) substructures, including the LA body, appendage (LAA), and pulmonary veins (PVs), from computed tomography (CT) is central to electroanatomic mapping for ablation and functional studies in patients with atrial fibrillation (AF). However, this process requires manual outlining which needs special training, is subjective, and is difficult to scale. Computer graphics imaging (CGI) has been applied in media, film, and computer-aided design to reliably segment complex structures using their basic geometric representations.
Purpose
We hypothesized that LA substructures can be “virtually” dissected using CGI to separate geometric contours of the “convex ellipsoid” LA, “tubular” PVs, and “conical” LAA. We further hypothesized that the results of virtual dissection can be used to train a deep learning (DL) model to segment raw CT scans.
Methods
First, a mathematical method based on CGI techniques – erosion and dilation – was developed to “virtually dissect” the convex LA body from the original concave shell in publicly available digital atria with diverse simulated morphologies (Fig. 1A). The PVs and LAA were then automatically revealed and labeled by a 3D subtraction approach. Second, we refined precise LA/PV/LAA boundaries by tuning hyper-parameters from N=5 patient shells (Fig. 1B). Third, we used virtual dissection to train a DL model to segment CTs in N=20 patient atria (Fig. 1C). Finally, we applied this pipeline to segment raw CTs in a validation cohort of N=105 patients (23.8% women, 63.8±10.3Y; Fig. 1D).
Results
Virtual dissection accurately identified LA/PV/LAA boundaries in the training set (Dice coefficients 89–98%). In the independent test cohort (N=105), this automated pipeline accurately segmented raw CTs with Dice 81–95% (Fig. 1D) compared to a panel of experts (p<0.001).
Conclusion
CGI of basic cardiac geometry combined with deep learning in small datasets can accurately segment raw CT scans in large populations. This computational pipeline may automate and simplify cardiac image processing and ablation procedures, and could be applied to the ventricle or other organ systems for diverse therapeutic strategies or to train machine learning.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Institutes of Health
Collapse
Affiliation(s)
- R Feng
- Stanford University, School of Medicine , Palo Alto , United States of America
| | - B Deb
- Stanford University, School of Medicine , Palo Alto , United States of America
| | - P Ganesan
- Stanford University, School of Medicine , Palo Alto , United States of America
| | - A J Rogers
- Stanford University, School of Medicine , Palo Alto , United States of America
| | | | - P Clopton
- Stanford University, School of Medicine , Palo Alto , United States of America
| | - F V Tjong
- Amsterdam UMC , Amsterdam , The Netherlands
| | - H J Chang
- Stanford University, School of Medicine , Palo Alto , United States of America
| | - M Rodrigo
- University of Valencia , Valencia , Spain
| | - M Zaharia
- Stanford University, Computer Science , Palo Alto , United States of America
| | - S M Narayan
- Stanford University, School of Medicine , Palo Alto , United States of America
| |
Collapse
|
45
|
Ruiperez-Campillo S, Deb B, Feng R, Ganesan P, Tjong FVY, Clopton P, Rogers AJ, Narayan SM. Artificial intelligence to reduce artifact in cardiac electrophysiological signals. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Signals in Electrophysiology cases are often noisy despite laboratory shielding and filtering, and current noise-reduction methods are suboptimal. Template matching can identify a “nearest type” of electrogram, but libraries of signal shapes may be unavailable. Beat averaging can reduce noise but obscures beat-to-beat variations and is not optimal to analyze dynamically changing signals, such as when moving a catheter in the heart. Smoothing reduces noise yet blurs high frequency components.
Purpose
We set out to test if machine learned autoencoders could reduce noise in single beats without requiring massive training data or beat libraries. Specifically, we hypothesised that noisy electrograms in small datasets of atrial signals could be de-noised using an encoder-decoder neural network (NN) using transfer learning of machines trained to recognize key features in larger datasets of related signals.
Methods
We applied NN to monophasic action potentials (MAPs), because they have visually verifiable shapes. The NN was first trained to reconstruct 5706 left and right ventricular MAPs in 42 patients (67±13y; Fig. 1A). Transfer learning was then used to apply the NN to a much smaller dataset of 641 atrial MAPs in 21 patients (67±5y, 13 women; Fig. 1B, D, F).
Results
NN reconstructed atrial MAPs with a Pearson correlation of 0.87±0.11. After fine-tuning, NN reconstruction accuracy improved dramatically (Pearson 0.99±0.01; p<0.001). In Fig. 1B–G the NN learned key MAP features (upstroke, triangular descent, terminus) and thus could eliminate ventricular artifact and electrical circuit noise without specific training or manual annotation.
Conclusion
Machine learned autoencoders are a novel and powerful approach to de-noise electrophysiological signals in a dynamic, beat-to-beat fashion. The ability to learn fundamental signal features from models trained in large datasets, and apply them via transfer learning to small datasets in different heart chambers may have wide ranging applications for automated signal annotation, mapping and ablation.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): NIH
Collapse
Affiliation(s)
- S Ruiperez-Campillo
- Stanford University School of Medicine , Palo Alto , United States of America
| | - B Deb
- Stanford University School of Medicine , Palo Alto , United States of America
| | - R Feng
- Stanford University School of Medicine , Palo Alto , United States of America
| | - P Ganesan
- Stanford University School of Medicine , Palo Alto , United States of America
| | - F V Y Tjong
- Stanford University School of Medicine , Palo Alto , United States of America
| | - P Clopton
- Stanford University School of Medicine , Palo Alto , United States of America
| | - A J Rogers
- Stanford University School of Medicine , Palo Alto , United States of America
| | - S M Narayan
- Stanford University School of Medicine , Palo Alto , United States of America
| |
Collapse
|
46
|
Li X, Feng R, Xia C, Ding S, Luo P. 1102P Genomic alterations correlated with the expression of PD-L1 based on the next-generation sequencing in Chinese non-small cell lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
47
|
Okekunle A, Feng R, Li C. Association of branched-chain amino acids consumption with obesity and diabetes mellitus in human populations. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Grinnell M, Concha J, Feng R, Keyes E, Okawa J, Diaz D, Vazquez T, Werth V. 278 Photo validation study using cutaneous dermatomyositis disease area and severity index in dermatomyositis patients. J Invest Dermatol 2022. [PMCID: PMC9296961 DOI: 10.1016/j.jid.2022.05.286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
49
|
Chin F, Vazquez T, Patel J, Feng R, Werth V. 840 Unsupervised learning reveals different degrees of heterogeneity as well as cell involvement in cutaneous lupus erythematous antimalarial treatment response subgroups. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.854] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
50
|
Dan J, Concha J, Sprow G, Feng R, Afarideh M, Kodali N, Vazquez T, Diaz D, White B, Werth V. 238 Cutaneous dermatomyositis area and severity index activity score (CDASI-A) and associated patient-reported outcomes in a phase 2 clinical trial in dermatomyositis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|